OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

OFFICE OF HEALTH ECONOMICS

----- Start of picture text -----
ohe.org
----- End of picture text -----

----- Start of picture text -----
0
----- End of picture text -----

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

2025

OFFICE OF HEALTH ECONOMICS Annual Charity Report

Graham Cookson

Office of Health Economics, London

Mireia Jofre-Bonet Office of Health Economics, London

Tim Watson Office of Health Economics, London

Charlotte Ashton

Office of Health Economics, London

Claire Green Office of Health Economics, London

Julia Toth Office of Health Economics, London

Lishani Ramanayake Office of Health Economics, London

Kelsey Moore Office of Health Economics, London

Megan Skingle Office of Health Economics, London

----- Start of picture text -----
1
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Table of contents

About OHE 3
Snapshot of the year 5
Charitable activities & impact 7
Strategic Research Themes 11
Project spotlights 20
Our growing global footprint 22
Our research outputs 24
Engagement & dissemination 26
Financial Review 29
Grants & Contract Research 31
Structure, Governance & Management 34
Appendices 36

----- Start of picture text -----
2
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

About OHE

Mission Support better health care policies by providing insightful economic and statistical analyses of critical issues.

The Office of Health Economics (OHE) is a charity with registered charity number 1170829. A senior management team manages OHE, and our governance is the responsibility of the Board of Trustees.

----- Start of picture text -----
3
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

About OHE

The Office of Health Economics (OHE) is a charity with registered charity number 1170829. A senior management team manages OHE, and our governance is the responsibility of the Board of Trustees.

The Board of Trustees has three sub-committees with advisory roles:

The Office of Health Economics wholly owns OHE Consulting Limited, which carries out consulting work for third parties. Its profits are gift-aided to OHE and fund our research and charitable activities.

OHE is an Independent Research Organisation (IRO). This status was awarded in 2020 by UK Research and Innovation (UKRI) which – through the seven Research Councils, Innovate UK and Research England – allocates more than £8.8 billion in research funding, primarily from the Department for Science, Innovation, and Technology’s (DSIT) R&D budget.

IRO status recognises the high quality of OHE’s independent research, on par with the UK’s higher education institutions, and makes us eligible to apply for UKRI funding on the same terms to better fulfil our charitable aims.

Priorities

We emphasise projects that tackle impactful policy and strategic issues with current and future significance. Our work involves stakeholders, clients, and external experts to obtain crucial new policy insights and identify strategies and optimal choices.

Although OHE is based in London, we undertake projects both in the UK and internationally. We work collaboratively with a wide network of academics and other partners worldwide.

----- Start of picture text -----
4
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Snapshot of the year

Our research and dissemination activity in 2025 reached further and covered more ground than ever before.

We continued to work on a broad range of topic areas – from drug pricing reform to antimicrobial resistance – reaching a wide range of audiences around the world.

----- Start of picture text -----
5
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Snapshot of the year

2025 was a year of growth across every part of our work. We published 43 research articles, 26 of them in external peer-reviewed journals, alongside 26 Insights and 22 Bulletins, and won 12 new research grants worth £1.12 million.

Our team delivered 122 presentations at conferences and policy events in the UK and internationally, hosted the UK’s longest-running academic health economics conference in Brighton and drew over 325 registrations to the OHE Annual Lecture.

Publication downloads rose 26% to 9,487, LinkedIn followers grew 30% to 16,512, and our fastest-growing audiences were in the Middle East and Asia-Pacific. The figures below set out the year at a glance.

----- Start of picture text -----
6
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Charitable activities & impact

Each year we deliver on our Charitable Objects and maintain our social purpose, where the charitable objects are:

----- Start of picture text -----
7
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

----- Start of picture text -----
8
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

----- Start of picture text -----
9
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

----- Start of picture text -----
10
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Strategic Research Themes

In 2025, OHE’s research was organised across four interlinked themes that underpin our ambition to shape smarter policies, foster innovation, and improve health every day.

----- Start of picture text -----
11
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT ANNUAL CHARITY REPORT

Climate & health

We address the complex intersection of climate change and health through research, events, and policy work. In 2025 we started ECO-CHICA, a Wellcome Trust funded project with LSHTM valuing the health cobenefits of climate mitigation. We also awarded our Policy Innovation Prize for sustainable innovation, and examined how the NHS is performing against its sustainability goals.

ohe.org ohe.org

12 12

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Climate & health

The climate crisis affects health in ways that are wide-ranging, unevenly distributed, and difficult to isolate. It poses deep challenges not only for service delivery but for how we define value, whose preferences we measure, and how we account for intergenerational and regional equity. Addressing the intersection of health and climate is therefore a cornerstone of OHE’s work, and in 2025 we began the year by awarding our Policy Innovation Prize jointly to two proposals for incentivising environmentally sustainable innovation in the life sciences, and went on to publish Insights, host events and start new research addressing this topic.

Our largest project in this area is ECO-CHICA, a Wellcome Trust-funded collaboration with the London School of Hygiene & Tropical Medicine (GHECO and CCPH) and the EuroMediterranean Center on Climate Change (CMCC). The grant (£156,284, via LSHTM) was awarded in December 2024 and was live throughout 2025. The project develops methods to value the health co-benefits of climate change mitigation, contributing to OHE’s growing portfolio at the intersection of health and environmental economics. Early outputs included a published protocol for a literature review on guidance for the economic evaluation of the health impacts of climate action (Wellcome Open Research, 2025).

On 8 July 2025 we hosted the webinar ‘Valuing health in an era of climate crisis: informing policy through economic evidence’, on the role of health economics in informing just, sustainable and evidence-based decision-making. We also examined how the NHS is performing against its sustainability goals, and our research portfolio grew to include work on the decarbonisation of health and social care under our Policy, Organisation and Incentives in Health Care Systems theme.

In further outreach, OHE also presented on health, climate and sustainability at international conferences including the Global Sustainable Development Congress 2025 in Istanbul.

Our Policy Innovation Prize, awarded on 24 January 2025 at its second award ceremony, distributed £40,000 to the winners, Professor Andrew Briggs and Professor Thomas Pogge, for proposals on how economic policies can incentivise environmentally sustainable innovation in the life sciences.

----- Start of picture text -----
13
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT ANNUAL CHARITY REPORT

Prevention

We prioritised prevention in 2025 through our commentary on financing prevention in the NHS 10 Year Health Plan and our Annual Lecture delivered by Professor Anita Charlesworth. Our work on the socioeconomic value of adult immunisation and the business cost of respiratory infections continue to have an impact internationally. Key research findings included adult vaccines returning up to 19x their investment, cervical cancer's £406 million preventable UK burden, and respiratory infections costing £44 billion in productivity losses – all receiving significant media coverage.

ohe.org ohe.org

14 14

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Prevention

With the UK Government’s NHS 10 Year Health Plan and this year’s Annual Lecture focused on prevention and related topics, OHE has contributed to national and global dialogue and debate on prevention and prioritised this line of research.

On the NHS 10 Year Health Plan, we provided commentary and insight to major media outlets, including the Financial Times and the Guardian, before, during and after the UK Government published its plan, with a focus on financing prevention and on elevating health above short-term political cycles. Chief Executive Graham Cookson argued in the Financial Times for a new consensus on prevention, and OHE published two comment pieces in Public Sector Focus on prevention financing and the move towards a digitally enabled workforce. The 10 Year Plan was also the topic of our Annual Lecture, given by Professor Anita Charlesworth, and the subject of a series of Insights on our website.

Our 2024 report on the socio-economic value of adult immunisation continued to have international impact in 2025 through media coverage (including CNN Greece, FORTUNE Italy, Health Service Journal and Healthcare Asia), a citation in a House of Lords briefing on incorporating societal and economic benefits in vaccine HTA, and invitations to high-level forums including the Global Vaccination Summit and a colloquium at the French Ministry of Health. Follow-on peer-reviewed articles on the broader socio-economic value of adult respiratory vaccination in the UK and Japan were published in Expert Review of Vaccines, and a ten-country cost-benefit analysis in Human Vaccines & Immunotherapeutics.

Our research into the business cost of respiratory infections reached policymakers, industry and the public throughout 2025. This research was cited by columnist Polly Toynbee in the Guardian and in a letter to the Telegraph by Director Amanda Cole. The findings also informed an OHE submission to a parliamentary inquiry on the ageing workforce, and featured in CEO Graham Cookson’s panel discussion at Economist Impact’s Future of Health Summit. In addition, we developed an interactive tool that lets businesses estimate their own costs, which also received media coverage. The work supports the prevention agenda by showing that short-term respiratory infections are an underestimated drain on employees, businesses, and the economy.

Our prevention research also shaped public debate on end-of-life and dementia care in 2025. Our work on unrelieved pain in palliative care featured in a BBC News segment ahead of the assisted dying debate, as well as on LBC Radio and in the Daily Mirror, and was cited by columnist Polly Toynbee in the Guardian. Separately, our research on dementia care was covered on BBC Radio 4 and BBC Radio Lancashire.

Finally, Senior Principal Economist Simon Brassel wrote to the Guardian on expanding where vaccines are administered in response to rising measles cases.

----- Start of picture text -----
15
----- End of picture text -----

ohe.org ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT ANNUAL CHARITY REPORT

Health Technology Assessment

We demonstrated HTA expertise in 2025 through peer-reviewed work on HTA reforms across agencies and early HTA, and our international "Around the World in HTAs" series, extended to Canada, Kenya and Argentina, was our most-read and highest-performing content of the year. Closer to home, OHE commentary on the NICE cost-effectiveness threshold informed the national conversation around the change.

16 166

ohe.org ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Health Technology Assessment

OHE’s ongoing expertise in Health Technology Assessment (HTA) was reflected in 2025 in our publications and engagement: our highest-performing content on LinkedIn, our mostdownloaded reports and our most-read Insights were all in the area of understanding HTA practices globally, including how HTA agencies set standards and influence one another.

Our peer-reviewed outputs this year included a comparative analysis of HTA reforms across agencies – processes, drivers and interdependencies (International Journal of Technology Assessment in Health Care, commissioned and funded by MSD), a consensus definition of early HTA developed with an HTAi working group, and work applying early HTA to inform investment in novel health technologies in the US.

We continued our international outlook on HTA developments with our ‘Around the World in HTAs’ Insight series, extended in 2025 to cover Kenya, Canada and Argentina, with four more editions in the pipeline. This series was among OHE’s most-downloaded and most-read output and our highest-performing content on LinkedIn.

Our Insights and publications continued to demonstrate our expertise on NICE decision making. OHE spokespeople were approached for comment on the review of the NICE costeffectiveness threshold, resulting in an interview in the Pharmaceutical Journal and an Insight on the threshold review.

OHE spokespeople continued their thought leadership in this area, and on 28 January 2025 we hosted a roundtable with a Department for Business and Trade Andean Regulatory Mission on regulatory and HTA processes in England and the international influence of NICE.

We also contributed to HTA capacity-building internationally through presentations at conferences including ISPOR Montreal and Arab Health Dubai, and through our BRAVER roadmap to broader assessment of the value of health interventions in the Asia-Pacific region, one of our most-downloaded reports of the year.

----- Start of picture text -----
17
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT ANNUAL CHARITY REPORT

Innovative pricing & drug development

In 2025, OHE shaped global debate on pharmaceutical pricing and access — most notably through high-profile analysis of the US 'Most Favoured Nation' proposals that reached policymakers and media in the UK and abroad, while publishing peer-reviewed research on combination therapy valuation, alternative payment models, biosimilars markets and biopharmaceutical investment, and contributing evidence to UK and Japanese parliamentary inquiries on medicine shortages.

18 188

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Innovative pricing & drug development

OHE has played an active role in shaping national and international debates on pharmaceutical policy, pricing, and access. In 2025 we responded to the US ‘Most Favoured Nation’ drug pricing proposals, focusing on the potential impact both in the US and internationally. Director Amanda Cole was interviewed in the British Medical Journal and POLITICO on the impact on industry and patient access in the UK, and Chief Executive Graham Cookson spoke to POLITICO on the policy’s effects on pricing abroad, in coverage syndicated widely, including on Oireachtas TV. OHE spokespeople were also frequently approached by reporters at The Times, the Financial Times and the Economist to provide context and information around the US–UK Pharmaceutical Agreement.

US drug pricing reform was also the topic of Graham’s opening remarks at ISPOR Montreal, which was later cited in the Pink Sheet. Our analysis also reached audiences through Insights and social channels, with our Insight explaining the levers at play with US drug pricing being the second most read Insight of the year.

OHE publications this year addressed critical challenges, including a general outcome-based value attribution framework for combination therapies (Value in Health), a framework for the effective implementation of alternative payment models for innovative medicines (Applied Health Economics and Health Policy), the price effects of biosimilars in the United States and a framework for sustainable global biosimilars markets, and an analysis of how the US Congressional Budget Office’s model of biopharmaceutical investment decision-making compares with investor insights (Health Affairs Scholar).

OHE submitted written evidence to a UK Parliamentary inquiry on medicine shortages, drawing on previous research on drug shortages. We were also invited to present our findings on the global implications of drug shortages at a study session at the Japanese Diet.

Our core-funded research under the Economics of Innovation theme examined biosimilar market dynamics, diversity of supply in rare-disease markets, pharmaceutical regulation after Brexit, and the commercial case for investment in ALS.

OHE’s research and perspectives continued to reach broad audiences through media and stakeholder engagement, with our ‘Most Favoured Nation’ analysis in particular featuring in prominent UK and EU outlets, and a brown-bag seminar on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG).

----- Start of picture text -----
19
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Project spotlights

Beyond our work in our three priority areas, there were a wide range of other impactful projects that saw great progress in 2025. Here are just a few more:

----- Start of picture text -----
20
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Project spotlights

Around the World in HTAs

Understanding HTA practices globally was OHE’s top-performing content area of 2025, with the Around the World in HTAs series driving our highest LinkedIn engagement, our most-downloaded reports and our most-read Insights.

New HORIZON grants: TEN4CARE and PREDICT FTD

TEN4CARE is a HORIZON grant awarded in September 2025 (£306,544) on an injectable and implantable nanocomposite hydrogel for tendon and ligament repair. The award reflects the dividends from networks and relationships built through previous European projects.

PREDICT FTD is a HORIZON grant awarded in January 2025 (£263,512) on the societal costs of frontotemporal dementia and the economic value of biomarker-led early diagnosis. Both projects sit within our Value, Affordability and Decision Making research theme.

----- Start of picture text -----
21
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Our growing global footprint

In 2025, OHE continued to deepen its international engagement, reflecting a strategic commitment to global collaboration and impact.

Building on its longstanding reputation for thought leadership in health economics and policy, OHE extended its reach through international research partnerships, our Around the World in HTAs series and presentations at major international conferences including ISPOR Montreal, Arab Health Dubai and the Global Sustainable Development Congress in Istanbul.

Our presence at international forums, participation in regional policy dialogues, and contributions to crossborder research projects have not only amplified our voice but also enriched our perspectives.

----- Start of picture text -----
22
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Our growing global footprint

As we continue to grow our global network, this section highlights the milestones, collaborations, and regional focus areas that are shaping OHE’s internationalisation journey. From new strategic alliances to region-specific research priorities, we are proud to share how OHE is helping to shape health policy and economics on a truly global scale.

The Middle East was our fastest-growing region in 2025. Graham Cookson spoke on two panels at Arab Health in Dubai, and Charlotte Ashton joined two panels at Abu Dhabi Global Health Week and met Bahrain’s Minister of Health. We began providing HTA advisory services to the Abu Dhabi Department of Health, and Martina Garau represented OHE at the HTAi and Tunisian Ministry of Health MENA regional meeting in Tunis. Our work was covered by the Bahrain News Gazette, the Bahrain News Agency, Al Ayam and Al Bilad.

Elsewhere, we launched the BRAVER report with the ISPOR Singapore chapter in Asia and established a new Policy Horizons series in the US, jointly funded by GSK and Bristol Myers Squibb. This activity is reflected in our reach: LinkedIn followers grew by 575% in the Middle East, 91% in Asia-Pacific, 49% in Africa, 48% in South America, 29% in North America and 19% across the UK and Europe. OHE speakers appeared at events in the UK (29), Europe (18), North America (10), the Middle East (8), Asia-Pacific (6) and South America (2).

2025 Global Partnerships

----- Start of picture text -----
23
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Our research outputs

We present our publications in five main groups:

Our research activities resulted in 43 publications in 2025, alongside 26 Insights and 22 Bulletins.

----- Start of picture text -----
24
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Our research outputs

OHE published 43 research articles in 2025: 26 in external peer-reviewed journals and 17 as OHE peer-reviewed publications. This compares with 22 and 14 respectively in 2024, increases of 18% and 21%. We also increased our output of Insights, Bulletins, and News Updates by 27% compared with 2024. We published 26 Insights (an 18% increase) and moved our Bulletin to twice monthly, raising the total from 16 in 2024 to 22 in 2025 (a 38% increase). Recent Insights addressed the government’s 10-year plan for the NHS, the review of the NICE cost-effectiveness threshold, and the expansion of the HTAs Around the World series to include Kenya, Canada, and Argentina.

In the last five years, 62 OHE-authored peer-reviewed journal articles have now accrued 10 or more citations, 34 have 20 or more, eight have 50 or more and six have passed 100. The full breakdown by year of publication is given in Appendix A , along with details of the ten most cited OHE journal articles since 2020. Some articles are published in highimpact journals and thus strengthen OHE’s reputation as an independent research organisation and ensure our work informs both academic and policy communities.

Our OHE peer-reviewed publications serve our mission well to advance health economics and evidence-based policy. Covering themes from value assessment and HTA reform to biosimilars, vaccination, and health system resilience, these articles contribute to global debates and practical solutions for sustainable healthcare.

Among these commissioned outputs, the ones with highest engagement included Averting the Trajectory of HIV in Europe (405 downloads), Taking STRIDES: The Value of Diagnostics Against AMR (282 downloads), and The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region (298 downloads).

Core-funded research remained active, with 12 active projects. Several led to journal publications, including Navigating Change: A Comparative Analysis of Health Technology Assessment Reforms Across Agencies (IJTAHC, 2025) and Effect of Caregiver Burden on the Quality of Life of Informal Caregivers of People with Cystic Fibrosis in the United Kingdom (Quality of Life Research, 2025). Others progressed through data collection and manuscript drafting, with further submissions expected in early 2026.

A full list of the ongoing core-funded projects, arranged by Research Theme, can be found in Appendix B . Overall, our core-funded pipeline reflects our commitment to support work that is relevant for both health economic methods and health policy.

----- Start of picture text -----
25
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Engagement & dissemination

OHE delivered a broad programme of educational activities in 2025 across virtual, in-person and hybrid formats, including specialised webinars, workshops, the second Innovation Policy Prize award and our Annual Lecture.

OHE also organised and hosted the Summer 2025 meeting of the Health Economics Study Group (HESG) in Brighton, the UK’s longest-running academic health economics conference, bringing together around 200 participants. This section provides an update on all the OHE events held over 2025.

----- Start of picture text -----
26
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Engagement & dissemination

Webinars

Roundtables

OHE external events

Brown-bag lunch seminars

Finally, we also hosted four different brown-bag lunch seminars:

----- Start of picture text -----
27
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Website, Insights & social media

Activity on our website and social media channels grew steadily throughout 2025. We launched a newly redesigned website with improved navigation, search, and search-engine performance. Publication downloads rose 26% to 9,487 (from 7,529 in 2024) and total website visits grew 6% to 122,021 (from 115,220). Our mailing list grew 7% to 12,171 subscribers; total unique opens rose 62% to 43,987 and unique clicks rose from 2,689 to 4,474, while the email bounce rate fell by 33% (from 207 to 139).

On LinkedIn we grew 30%, gaining 3,763 new followers (compared with 2,823 in 2024) to more than 16,512 by year end, and introduced the ‘In Focus’ series highlighting key publications. Our X (Twitter) following was broadly stable at 5,872 (up 0.5%), reflecting reduced activity on the platform.

External presentations

The 122 presentations delivered in 2025 were given by 33 OHE team members at conferences, webinars, workshops and policy events in the UK and internationally. Topics spanned health economics methods, HTA, rare diseases, vaccination and antimicrobial resistance, workforce and system performance, environmental sustainability, and the economic evaluation of climate and public health interventions, with audiences ranging from small academic sessions to large international conferences including ISPOR Montreal, Arab Health Dubai, and the Global Sustainable Development Congress in Istanbul. The full list can be found in Appendix C .

Advisory Roles

The number of advisory roles held by OHE staff members has continued to grow, reflecting their strong influence on policy and their recognised contributions to the research and policy community. This impact aligns with OHE’s charitable objective of steering health policy and decision-making in health economics and building capability by transferring health economics research skills to students and other individuals at different stages of their careers. A full list of OHE staff memberships of advisory panels, boards and committees is given in Appendix D .

----- Start of picture text -----
28
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Financial Review

In 2025, OHE remained an organisation undertaking research and related activities according to its charitable objects and status of independent research organisation. OHE owns the sole share in OHE Consulting Limited with the purpose of enabling OHE to:

----- Start of picture text -----
29
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Financial Review

Financial Performance in 2025

The financial statements of OHE comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts following The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) (“Charities SORP FRS 102“).

OHE’s consolidated turnover (OHE and OHE Consulting Limited) in 2025 was £5.69m , compared with £5.24m in 2024. Expenditure totalled £5.23m , leaving a net income of £457k. Of the estimated expenditure, staff costs in 2025 amounted to approximately £3.57m , or around 68% of the total.

The consolidated accounts for OHE are included as an Annex to this report.

Sources of Funding

The sources of funding for OHE are summarised below. The financial reports attached provide more details about OHE income and expenditure.

The estimated consolidated income of £5.69m comprises:

The estimated consolidated income of£5.69mcomprises:
£000
Donations – research grants 302
Income from charitable (research) activities* 948
Interest 23
Total research income 1,274
OHE Consulting Income 4,415
Total Income 5,688
Donations are from the ABPI and are for two distinct purposes:
£000
Support for core research activities 100
Grant towards fnancing of support activities 396
Total 496

*Income from charitable (research) activities came from several sources. Major research projects and funders included: HORIZON European Commission Grants (including TEN4CARE and PREDICT FTD), Wellcome Trust (ECO-CHICA), the Change Initiative, EuroQol Research Foundation and Parkinson’s UK.

Reserves and going concern

Revenue has grown consistently over the decade since OHE became a charity, with a single loss (2023). At 31 December 2024, reserves were £1.57m. Given the estimated 2025 surplus, reserves are expected to exceed £2m, estimated at around £2.3m, equivalent to roughly 44% of forecast 2026 expenditure or 56% of staff costs.

A consistent record of revenue growth, predictable surpluses, and significant reserves indicates that OHE is a stable and sustainable charity and can be regarded as a going concern. OHE’s reserves policy is to hold three to six months of payroll costs as cash reserves; as a large charity, OHE will review this policy at the March 2026 Board meeting and has requested a written going-concern assessment from its auditors ahead of the June 2026 Board meeting.

----- Start of picture text -----
30
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Grants & Contract Research

The number and amount of research grant funded projects in 2025 amounts to £3.87 million, 49% higher than at the end of 2024 (£2.6 million).

The pipeline and the research grant applications show that 2025 was a record year for OHE research grant income. New research grants awarded in 2025 amount to £1.12 million (up 19%), the value of lost applications fell 45%, and networks built through previous European HORIZON projects continued to pay dividends, including the TEN4CARE grant.

Contract research also had a strong year, with 84 new contracts won in 2025 worth a combined £5.22 million and a year-end pipeline of 51 opportunities valued at £7.07 million (£3.95 million on a probability-adjusted basis).

----- Start of picture text -----
31
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Grants & Contract Research

2025 Research Grants Activity

Key takeaways:

Government and other grant income received in 2025 is reported to the Charity Commission through the annual return. OHE’s research grant activity strengthened markedly during the year. The value of live grant-funded research projects at the end of 2025 was £3.87m, 49% higher than at the end of 2024 (£2.6m). The total value of new research grants awarded in 2025 was £1.12m, 19% higher than in 2024 (£0.94m). Networks built through previous European projects continued to pay dividends: in 2025 we secured a further HORIZON grant (TEN4CARE) and submitted further applications. Our contract research portfolio also grew, with new live contracts worth £5.0m by year end (94% higher than £2.6m in 2024) and a pipeline worth £3.9m (£2.2m in 2024).

As of December 2025, OHE held 12 new grants won in 2025 with a combined budget of £1.1m, 14 ongoing projects from previous years totalling £1.74m, and projects closed during 2025 worth £1m, giving a combined live portfolio of £3.87m. Projects are classified under the four research themes: Value, Affordability and Decision Making (VADM); Policy, Organisation and Incentives in Health Care Systems (POIHS); Economics of Innovation (EoI); and Measuring and Valuing Outcomes (MVO).

PROJECTS WON IN 2025

The new projects won during 2025 were funded by bodies including the European Commission, Innovate UK, Nesta, the EuroQol Research Foundation, the National Institutes of Health, the CML Advocates Network and the Universities of Sussex and Manchester. The full list, with project title, theme, year won and budget, is given in Appendix E .

PROJECTS WON PRIOR TO 2025 AND STILL LIVE

Thirteen projects won in earlier years remained live during 2025, funded by bodies including the European Commission, the CML and Acute Leukaemia Advocates Networks, the London School of Hygiene & Tropical Medicine, the EuroQol Research Foundation and High Flow Therapy UK. The full list, with project title, theme, year won and budget, is given in Appendix E .

----- Start of picture text -----
32
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

PROJECTS WON PRIOR TO 2025 AND CLOSED IN 2025

Seven projects won in earlier years were completed and closed during 2025, including work for IFPMA, the Health Foundation, Amicus Therapeutics, Curta, Parkinson’s UK and UCL. The full list, with project title, theme, year won and budget, is given in Appendix E .

PROJECTS IN THE PIPELINE (AS OF DECEMBER 2025)

OHE’s grant pipeline remains strong. The table below lists proposals under consideration with their nominal value, the assessed probability of success, and the probability-adjusted value. The DG SANTE framework bid has no budget, being an accreditation that allows OHE to bid for European Commission DG SANTE projects in consortium.

Twenty-four proposals remained under consideration at the year end, led by submissions to the European Commission, the NIHR, the Fleming Initiative, Queen Mary University of London, the Acute Leukaemia Advocates Network, the EuroQol Research Foundation and Verian. Nominal and probability-adjusted values for each proposal are given in Appendix E .

Projects shown at £0 were still being costed at year end. Adjusted values apply the probability of success to the nominal budget.

PROJECTS SUBMITTED AND LOST IN 2025

In 2025, 12 grant proposals were unsuccessful, with a combined value of £2.5m, many of them large, multi-partner applications under Wellcome Trust, NIHR, and Horizon Europe calls. The value of lost applications fell 45% on 2024 (from £4.4m to £2.55m), reflecting a more selective application strategy.

Twelve proposals submitted during 2025 were unsuccessful, including bids to the NIHR, the Wellcome Trust, Science for Africa, UKRI, the Physicians Committee for Responsible Medicine, the EuroQol Research Foundation and Astellas Pharma US. The full list, with project title, theme and value, is given in Appendix E .

Contract research projects

Contract research is carried out by OHE Consulting Limited, the charity’s wholly owned subsidiary. In 2025 the subsidiary generated income of £4.42m, equivalent to 78% of OHE’s consolidated turnover of £5.69m, making it the largest single source of funds supporting the charity’s work. Its taxable profits are gift-aided in full to OHE, where they fund the independent research programme alongside grant income and donations from the ABPI.

Across the portfolio, contract research remained concentrated in Value, Affordability and Decision Making, which accounted for the majority of the value delivered during the year. Work under Economics of Innovation was generally smaller in scale, shorter in duration and more often dissemination-focused, while Policy, Organisation and Incentives in Health Care Systems and Measuring and Valuing Outcomes projects were fewer in number but typically of moderate value. The shape of the portfolio was barbelled, combining a small number of large multi-year studies with a long tail of short, low-value commissions. The pipeline at the year end points towards a shift, with health systems and policy work accounting for a larger share of expected value than in the delivered portfolio.

Project-level detail is not reported here. Individual contracts are commercially sensitive, and the work is undertaken by the trading subsidiary rather than as a charitable activity of OHE itself.

----- Start of picture text -----
33
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Structure, Governance & Management

----- Start of picture text -----
34
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Structure, Governance & Management

This is OHE’s ninth annual submission to the Charity Commission for England and Wales since registration as a charity in December 2016. The Board of Trustees sits at the top of OHE’s governance structure, supported by the Research Committee, the Policy Committee, and the Editorial Panel. The Research Committee guides OHE on research methods, oversees the core research grant programme, and assures the quality and independence of OHE’s research. The Policy Committee advises on policy impact and engagement, and the Editorial Panel guarantees the quality of OHE’s publications.

Trustee news in 2025

It is with great sadness that OHE records the death of Trustee and long-standing ABPI colleague Paul Catchpole during 2025. His contribution to OHE, the ABPI, and the wider healthcare sector was substantial and widely recognised. The ABPI appointed Victoria Jordon, Director of Value and Access at the ABPI, as his successor; she joined the Board at the December 2025 meeting.

Trustees

Anita Charlesworth, The Health Foundation (Chair) Richard Torbett, ABPI Werner Brouwer, ESHPM (appointed 31 March 2022) Patrick Holmes, Pfizer (appointed 31 January 2022) Thomas Allvin, EFPIA (appointed 23 February 2023) Victoria Jordon, ABPI (appointed December 2025)

Changes during the year: Paul Catchpole, ABPI (appointed 4 October 2023; died 2025); Margaret Kyle, Mines ParisTech (OHE) (resigned 31 December 2024)

Senior Management

Chief Executive Officer Prof Graham Cookson

Deputy Chief Executive Officer Prof Lotte Steuten Chief Research Officer and Head of Education Prof Mireia Jofre-Bonet

Directors Charlotte Ashton Martina Garau Chris Skedgel Tim Watson Associate Directors Amanda Cole Grace Hampson

Registered Office: 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB Charity number: 1170829; Company number: 09848965

Auditor: BDO LLP , Statutory Auditor & Chartered Accountants, 2 City Place, Beehive Ring Road, Gatwick, West Sussex RH6 0PA. Bankers: National Westminster Bank Plc, PO Box 113, Cavell House, 2A Charing Cross Road, London

----- Start of picture text -----
35
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS CONTRACT RESEARCH ANNUAL CHARITY REPORT

Appendices

36 65

ohe.org ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Appendix A — Publications

External peer-reviewed journal articles

For external peer-reviewed journal articles, we provide information on the sources of financial support, number of citations, SJR indicator and ABS journal ranking.

JOURNAL REFERENCE SOURCE OF CITATIONS SJR ABS
FINANCIAL (2024) (2024)
SUPPORT
Hitch J, Denee T, Brassel S, Lee J, Michaelides M, Petersen J, Contract 1 1.856 N/A
Alulis S, Steuten L. (2025) Challenges in Value Assessment research
for One-Time Gene Therapies for Inherited Retinal (Johnson &
Diseases: Are We Turning a Blind Eye? Value in Health. Johnson)
Jan;28(1):116-124.
https://doi.org/10.1016/j.jval.2024.08.009.Epub 2024 Oct
8. PMID: 39384069.
Steuten, L., Lothgren, M., Bruce, A., Campioni, M., & Towse, A. Contract 6 1.856 N/A
(2025). Proposal for a General Outcome-Based Value research
Attribution Framework for Combination Therapies. Value in (Amgen)
health: the journal of the International Society for
Pharmacoeconomics and Outcomes Research, 28(1), 81–
87.https://doi.org/10.1016/j.jval.2024.07.019
Buiteman–Kruizinga, L. A., Meenen, D. M. P. v., Neto, A. S., Unfunded 15 2.751 N/A
Mazzinari, G., Bos, L. D. J., Heiden, P. L. J. v. d., … & Schultz, M.
J. (2025). Association of ventilation volumes, pressures and
rates with the mechanical power of ventilation in patients
without acute respiratory distress syndrome: exploring the
impact of rate reduction. Anaesthesia, 80(5), 533-542.
https://doi.org/10.1111/anae.16537
Henderson RH, Sampson C, Pouwels XGLV, Harvard S, Unfunded 3 1.856 N/A
Handels R, Feenstra T, Bhandari R, Sepassi A, Arnold R.
(2025) Mapping the Landscape of Open Source Health
Economic Models: A Systematic Database Review and
Analysis: An ISPOR Special Interest Group Report. Value in
Health. Feb 12:S1098-3015(25)00060-9.
https://doi.org/10.1016/j.jval.2025.01.019. Epub ahead of
print. PMID: 39952464.
Roth, J.A., Dayer, V.W., Jofre-Bonet, M. et al. (2025) Defning Core funded 2 2.290 N/A
a Framework for Sustainable Global Biosimilars Markets research
Using Findings from a Targeted Literature Review. BioDrugs.
https://doi.org/10.1007/s40259-025-00710-8
Pinto, C., Norton, S., Cubi-Molla, P., Hurt, C., Chowdhury, S., Grant funded 0 1.356 N/A
Dooley, N., … Bogosian, A. (2025). Evaluating a digital mental research
health intervention for people with Parkinson’s (PACT): [Parkinson’s UK
acceptability and feasibility randomised controlled trial. under Grant ref:
Aging & Mental Health, 1–9. H-2102; PI was
https://doi.org/10.1080/13607863.2025.2478508 City St
George’s,
University of
London]

----- Start of picture text -----
37
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

JOURNAL REFERENCE SOURCE OF CITATIONS SJR ABS
FINANCIAL (2024) (2024)
SUPPORT
Hussain H, Keetharuth A, Wailoo A, Rowen D. (2025) EEPRU via 0 3.600 N/A
Enhancing HRQoL assessment for economic evaluation in University of
dementia populations. Alzheimer’s Dement; 11:e70061. Shefeld
https://doi.org/10.1002/trc2.70061
Kumar G, Radu P, Cubi-Molla P, et al. (2025) Navigating Contract 2 0.846 N/A
change: a comparative analysis of health technology research (MSD)
assessment reforms across agencies – processes, drivers,
and interdependencies. International Journal of Technology
Assessment in Health Care; 41(1):e21.
https://doi.org/10.1017/S0266462325000133
Pinto, C., Brown, J., Hurt, C. ...Jofre-Bonet, M. et al. (2025) Grant funded 0 0.672 N/A
Acceptability and feasibility randomised controlled trial of a research
digital mental health intervention for people with [Parkinson’s UK,
Parkinson’s (PACT): trial protocol. Pilot Feasibility Stud 11, PI was City St
32.https://doi.org/10.1186/s40814-025-01594-9 George’s,
University of
London]
McElwee, F., Cole, A., Kaliappan, G. et al. (2025) Alternative Contract 3 1.291 N/A
Payment Models for Innovative Medicines: A Framework for research
Efective Implementation. Appl Health Econ Health Policy. (Roche)
https://doi.org/10.1007/s40258-025-00960-1
Jofre-Bonet, M., Roig, M.R. & Serra-Sastre, V. (2025) No 0 0.760 2
Intimate partner violence and children’s cognitive
development. Empir Econ.https://doi.org/10.1007/s00181-
025-02746-9
Jofre-Bonet M, McGuire A, Dayer V, Roth JA, Sullivan SD. TBC 6 1.856 N/A
(2025) The Price Efects of Biosimilars in the United States.
Value in Health. May;28(5):742-750.
https://doi.org/10.1016/j.jval.2025.02.008.Epub 2025 Mar
4. PMID: 40049325.
Grutters JPC, Bouttell J, Abrishami P, Ahmed SYM, Cole A, No Funding 13 0.846 N/A
Dawoud D, Fernández-Barceló C, Frederix GWJ, Hawkins N,
Karnon J, Leadbitter S, McCabe C, Mueller J, Achiaw SO,
Partington A, Sampietro-Colom L, Seyahian A, Sucu R, Tew
M, van Katwyk S, Verboven Y, Wang Y; (2025) A Working
Group of HTAi. Defning early health technology
assessment: building consensus using Delphi technique. Int
J Technol Assess Health Care. Jun 2;41(1):e34.
https://doi.org/10.1017/S0266462325100123. PMID:
40452233; PMCID: PMC12178750.
Chowdhury, S., Cubi-Molla, P. & Mott, D. (2025) Efect of Core funded 0 1.436 N/A
caregiver burden on the quality of life of informal caregivers research
of people with cystic fbrosis in the United Kingdom: a
cross-sectional study. Qual Life Res.
https://doi.org/10.1007/s11136-025-04021-x
Theakston, C., Napier, M., Brassel, S., Kamei, K., Ito, S., Vietri, Contract 1 1.255 N/A
J., … Steuten, L. (2025). A beneft-cost analysis quantifying
the broader socioeconomic value of adult respiratory
research
(Pfzer)
vaccination programs in Japan. Expert Review of Vaccines,
24(1), 633–643.
https://doi.org/10.1080/14760584.2025.2536092

----- Start of picture text -----
38
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

JOURNAL REFERENCE SOURCE OF CITATIONS SJR ABS
FINANCIAL (2024) (2024)
SUPPORT
Harrison, C., Brassel, S., Chowdhury, S., Theakston, C., Napier, Contract
M., Vietri, J., Steuten, L. (2025). The broader socio-economic research
value of adult respiratory disease vaccinations in the UK –
results from a beneft cost analysis. Expert Review of
(Pfzer)
Vaccines, 24(1), 644–655.
https://doi.org/10.1080/14760584.2025.2536093
Cubi-Molla P, MacClancy C, Oyalo P et al. (2025) Guidance Grant Funded 2 0.693 N/A
on the economic evaluation of the health impacts of research
climate action: a literature review protocol. [version 1; peer Wellcome Trust
review: awaiting peer review]. Wellcome Open Res, 10:354 contracting
(https://doi.org/10.12688/wellcomeopenres.24029.1) from LSTHM
McGuire A, Wharton G, Hodgson S, Kourouklis D, Jofre- Core funded 1 1.026 N/A
Bonet M, Tran DL, (2025). Health system sustainability and research
resilience: a preliminary provision of measurement through
a “mash-up” index. Health Economics, Policy and Law., pp.1–
13. DOI:https://doi.org/10.1017/S1744133125100182.
Hussain, H. et al. (2025) Mapping EQ-5D-5L Utilities in EEPRU via 0 1.856 N/A
Dementia: Integrating Self and Proxy Reports. Value in University of
Health, Volume 28, Issue 8, 1204 - 1212 Shefeld
Elsisi Z, Canestaro W, Steuten L, Hansen R. (2025) Applying Core funded 0 0.846 N/A
early health technology assessment (e-HTA) to inform research
investment in novel health technologies in the US.
International Journal of Technology Assessment in Health
Care. 2025;41(1):e45.
https://doi.org/10.1017/S0266462325100275
Patel, A., Jofre-Bonet, M.,Hauck, K., Miraldo, M., Mistry, H.,
Premji, S. (2025). Broadening the lens: a commentary on
Sheard and Cauana-Finkel’s account of women’s progress in
UK academic health economics. Social Science & Medicine,
Volume 382,2025,118411
https://doi.org/10.1016/j.socscimed.2025.118411
Hitch, J., Kumar, G., Schneider, P. et al. (2025) The Infuence EuroQol 0 1.880 2
of Perspective on the Valuation of the EQ-5D-Y-3L: A Foundation
Comparison Using the OPUF Tool and a Discrete Choice
Experiment. PharmacoEconomics. https://d
oi.org/10.1007/s40273-025-01545-5
Matthias P Hofer, Priscila Radu, Mikel Berdud, Amanda Cole, PhRMA 0 N/A N/A
Graham Cookson, (2025) Understanding
biopharmaceutical investment decision-making: how does
Congressional Budget Ofce’s model compare to investor
insights?, Health Afairs Scholar, Volume 3, Issue 11,
November, qxaf200,
https://doi.org/10.1093/haschl/qxaf200
Miller, C.B., Bradley, D., Hall, S., Hayes, H., Chowdhury, S. and Big Health Inc. 0 0.897 N/A
Sampson, C., (2025). Cost Savings Associated With Fully
Automated Digital Cognitive Behavioral Therapy for
Insomnia Disorder (SleepioRx): A Matched Control Study of
US Patients. Journal of Health Economics and Outcomes
Research, 12(2), pp.193–199.
https://doi.org/10.36469/001c.146434.

----- Start of picture text -----
39
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

JOURNAL REFERENCE SOURCE OF CITATIONS SJR ABS
FINANCIAL (2024) (2024)
SUPPORT
Hughes DA, Fong H, Hampson G, Plumpton CO, Sampson C. Grant funded 0 1.155 N/A
(2025) Health economic considerations for research
pharmacogenomic services in the United Kingdom: The
Centre for Excellence in Regulatory Science and Innovation
in Pharmacogenomics. Br J Clin Pharmacol. 2025; 1-3.
https://doi.org/10.1002/bcp.70412
Chowdhury S, Brassel S, El Banhawi H, Bell E, Neri M, IFPMA
Steuten L. (2025) A cost-beneft analysis of adult
immunization programs across ten countries: Modeling the
socioeconomic value of immunization for older populations
compared to no vaccination. Hum Vaccin Immunother.
Dec;21(1):2602976.
https://doi.org/10.1080/21645515.2025.2602976.Epub
2025 Dec 18. PMID: 41410417; PMCID: PMC12716055.

Citations from Google Scholar as of January 2026. SJR is the SCImago Journal Rank indicator (latest year 2024). ABS is the Chartered Association of Business Schools journal ranking (4 highest to 1; latest 2024). N/A indicates no ranking available. Chartered Association of Business Schools (‘ABS’), UK: journal rankings go from 4 (highest) to 1 lowest).

Summary of citations over time, 2020–2025

NUMBER OF 2020 2021 2022 2023 2024 2025 Total
CITATIONS
10+ 10 18 19 10 3 2 62
20+ 8 11 11 2 2 0 34
50+ 3 2 3 0 0 0 8
100+ 3 0 3 0 0 0 6

----- Start of picture text -----
40
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Top 10 most cited publications since 2020

1. 2,256 Citations

Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., et al as part of the CHEERS 2022 ISPOR Good Research Practices Task Force 2022., Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. European Journal of Health Economics . (Epub ahead of print). DOI: 10.1007/s10198-021-01426-6.

2. 404 Citations

Mateo, J., Steuten, L., Aftimos, P., André, F., Davies, M., Garralda, E., Geissler, J., Husereau, D., Martinez-Lopez, I., Normanno, N., Reis-Filho, J., Stefani, S., Thomas, D., Westphalen, B., & Voest, E. 2022. Delivering Precision Oncology to Patients with Cancer. Nature Medicine. DOI: 10.1038/s41591-022-01717-2

3. 214 Citations

Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray JF, Koffijberg HE, Strong M, Sanders Schmidler GD, Rothery C. (2020) Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, Feb;23(2):139-150. doi: 10.1016/j.jval.2020.01.001. PubMed PMID: 32113617.

4. 129 Citations

Rothery C, Strong M, Koffijberg HE, Basu A, Ghabri S, Knies S, Murray JF, Sanders Schmidler GD, Steuten L, Fenwick E. (2020) Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health . Mar;23(3):277286. doi:10.1016/j.jval.2020.01.004. PubMed PMID: 32197720.

5. 112 Citations

Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M., 2019. Comparing access to orphan medicinal products in Europe. Orphanet Journal of Rare Diseases, 14(1), p.95. 10.1186/s13023-019-1078-5.

6. 104 Citations

Berdud M, Drummond M, and Towse A. (2020). Establishing a reasonable price for an orphan drug. Cost Effectiveness and Resource Allocation https://doi.org/10.1186/s12962-020-00223-x

7. 96 Citations

Steuten, L., Goulart, B., Meropol, N.J., Pritchard, D. and Ramsey, S.D. 2019. Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology , (3), pp. 1-10. DOI: 10.1200/CCI.19.00002.

8. 93 Citations

Sampson, C.J., Arnold R., Bryan, S., Clarke, P., Ekins, S., Hatswell, A., Hawkins, N., Langham, S., Marshall, D., Sadatsafavi, M., Sullivan, W., Wilson, E.C.F., and Wrightson, T. (2019) Transparency in decision modelling: what, why, who and how? PharmacoEconomics. DOI: 10.1007/s40273-019-00819-z.

9. 88 Citations

Wurcel, V., Cicchetti, A., Garrison, L., Kip, M.M., Koffijberg, H., Kolbe, A., Leeflang, M.M., Merlin, T., MestreFerrandiz, J., Oortwijn, W. and Oosterwijk, C., Tunis, S., Zamora, B. 2019. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics, pp.1-8.

10. 69 Citations

Mott DJ, Shah KK, Ramos-Goñi JM, Devlin NJ, Rivero-Arias O. (2021) Valuing EQ-5D-Y-3L Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ? Medical Decision Making. DOI:10.1177/0272989X21999607

----- Start of picture text -----
41
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

OHE peer-reviewed publications, funding, and number of downloads

PUBLICATION
ALTERING THE TRAJECTORY OF HIV IN EUROPE
https://www.ohe.org/publications/altering-the-trajectory-of-hiv-in-europe/
THE BRAVER ROADMAP TO BROADER ASSESSMENT OF THE VALUE OF
HEALTH INTERVENTIONS IN THE ASIA-PACIFIC REGION
https://www.ohe.org/publications/the-braver-roadmap-to-broader-assessment-
of-the-value-of-health-interventions-in-the-asia-pacifc-region/
UNDERSTANDING THE FULL VALUE OF LONG-ACTING THERAPIES: LESS IS
MORE? https://www.ohe.org/publications/understanding-the-full-value-of-long-
acting-therapies-less-is-more/
TAKING STRIDES: THE VALUE OF DIAGNOSTICS AGAINST AMR
https://www.ohe.org/publications/taking-strides-the-value-of-diagnostics-
against-amr/
ANALYSING GLOBAL IMMUNISATION EXPENDITURE
https://www.ohe.org/publications/analysing-global-immunisation-expenditure/
THE VALUE OF CELL AND GENE THERAPIES TO THE UK ECONOMY
https://www.ohe.org/publications/value-of-cell-and-gene-therapies-to-the-uk-
economy/
CHALLENGES AND SOLUTIONS FOR BUDGET IMPACT ANALYSIS OF GENE
THERAPIEShttps://www.ohe.org/publications/challenges-and-solutions-for-
budget-impact-analysis-of-gene-therapies/
AN ANALYSIS OF NICE’S OPTIMISED DECISIONS FROM 2015 TO 2024
https://www.ohe.org/publications/an-analysis-of-nices-optimised-decisions-from-
SOURCES OF
FINANCIAL SUPPORT
NUMBER OF
DOWNLOADS
Contract research (ViiV
Healthcare)
405
Contract research
(Roche, MSD, Johnson &
Johnson)
298
Contract research (GSK) 285
Contract research
(bioMérieux)
282
Contract research
(Pfzer)
150
Contract research (Cell
and Gene Therapy
Catapult)
132
Contract research
(Johnson & Johnson
Innovative Medicines)
118
Contract research (ABPI) 92
Contract research
(Amicus Therapeutics
UK)
91
Contract research (MSD,
AstraZeneca, GSK)
78
Grant-funded research
(Challenge Works,
Longitude Prize on ALS)
70

----- Start of picture text -----
42
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Appendix B— Core-funded projects:

Economics of Innovation

PROJECT INVESTIGATORS UPDATE ON PROGRESS Pharmaceutical policy and access Matthias Hofer, Phill O’Neill, Updates the first analysis of MHRA regulatory activity since 2021. to innovation in the UK after Brexit Mireia Jofre-Bonet Analysis of regulatory performance finalised with the help of an LSE MSc student and ready for dissemination in 2026; analysis of access to be progressed in 2026.

Value, Affordability and Decision Making

Value, Afordability and Decision Making
PROJECT INVESTIGATORS UPDATE ON PROGRESS
Defning Afordability Gayathri Kumar, Patricia
Cubi-Molla, Martina Garau,
Matthew Napier, Phill O’Neill,
Identifes how afordability has been defned and implemented in
the literature and UK policy debate and proposes a unifed
defnition across levels of decision-making. Completed.
Chris Sampson, George Bray
HTAs Around the World blog series Patricia Cubi-Molla, Martina An insight series on HTA arrangements country by country, each
Garau, Matthew Napier, Phill with an external co-author. Three insights published in 2025
O’Neill, Chris Sampson, (Kenya, Canada, Argentina), with four more in the pipeline.
George Bray, Henry Fong Ongoing.
ECO-CHICA manuscripts (x3) Patricia Cubi-Molla, Paul Co-authorship of the four key ECO-CHICA deliverables with
Oyalo, Hannah Hussain, LSHTM (literature review protocol, main results, deep dives, and
Mireia Jofre-Bonet fnal guidance). Completed.
Navigating change paper Patricia Cubi-Molla, Martina Examines variation in the positioning of 14 HTA agencies across
Garau (with G Kumar, P Radu
fve methodological topics and the drivers of change. Published
and co-authors) in 2025 (International Journal of Technology Assessment in
Health Care).

Policy, Organisation and Incentives in Health Systems

Project Investigators Update on progress
The efect of distance on accident Sian Besley Quantifes the relationship between travel distance and
and emergency department emergency-department demand using area-level regression.
demand Awaiting fnal analysis tables from external co-authors;
manuscript near completion.
Labour productivity and efciency Margherita Neri, Graham Estimates a general-practice production model using stochastic
of general practices in England Cookson (with E Zucchelli frontier analysis on 316 practices (2018–2021). Being updated
and B Hollingsworth) for resubmission to The European Journal of Health Economics.
Development of a synthetic index Patricia Cubi-Molla, Explores the feasibility of a synthetic index aggregating
of primary-care output in England Margherita Neri, Graham indicators of valued primary-care output, building on the Health
Cookson Foundation primary-care efciency grant. Ongoing; completing
the paper for submission to Applied Health Economics and
Health Policy.
Double burden of malnutrition Hania El Banhawi (with N Examines the prevalence and socioeconomic determinants of
among mother-child pairs in Batura and R Leiva- mother-child double burden of malnutrition in Nigeria. Imputing
Nigeria Granados, UCL) missing data for robustness and revising for journal submission.

Measuring and Valuing Outcomes

----- Start of picture text -----
43
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Project Investigators Update on progress
Quality of life of carers of patients David Mott, Sulayman Completed; published in 2025 in Quality of Life Research.
with cystic fbrosis Chowdhury, Patricia Cubi-
Molla
Spillover efects on informal and Claud Theakston, David Mott A systematic review cataloguing preference-based measures of
family caregivers’ utility caregiver utility, updating Wittenberg et al. (2019). Ongoing;
accepted as a poster at ISPOR Summer 2025; completing the
paper for submission.

----- Start of picture text -----
44
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Appendix C— External presentations, 2025

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
1 8th Chris Health Economists’ Study Group Bristol — Discussion of ‘Optimising allocation 50
January Sampson of healthcare resources with machine learning:
The case of personalised DR screening for
diabetes patients’ by Sasja Maria Pederson and
colleagues
2 9th Mireia HESG Meeting Winter 2025 Bristol — Outside Wage Dynamics, Turnover 20
January Jofre- and Hospital Performance - Evidence from the
Bonet English NHS’ panel discussion.
3 10th Mireia HESG Meeting Winter 2025 Bristol — ‘The efect of reductions in substance
50
January Jofre- misuse service expenditure on hospital
Bonet admissions in England ’.
4 10th s and the HESG Meeting Winter 2025 Bristol — Chris Sampson chaired the panel 50
January room to session discussing ‘Can we improve quality of
link care for Child and Adolescent Mental Health
methods Services in the English NHS within a resource
to constrained environment?’
implement
able
levers—
access,
continuity,
and
measurabl
e
quality—
rather
than
abstract
ideals.
(The
CAMHS
session’s
Discussan
t was
Apostolos
Tsiachista
s.
5 16th Graham Healthcare World Stage @ Arab Health Online — Future proofng healthcare 1700
January Cookson
6 22nd Charlotte Business Fights Poverty: Together for 2025 Online — Leadership for a Sustainable Future 200
January Ashton
7 23rd Amanda Gene People Leadership Symposium 2025 - Virtual — Real World Evidence (RWE): what it is —
January Cole Evidence and why it is so important for rare diseases?
8 24th Matthias Predict FTD project kick-of event Rotterdam — Economic analysis for Predict —
January Hofer, FTD
Sulayman
Chowdhur
y, Mireia

----- Start of picture text -----
45
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
Jofre-
Bonet
9 29th Graham Arab Health Conference Dubai C, Dubai World Trade Centre —
January Cookson — Health Systems of the Future Panel
Discussion
10 29th Graham Arab Health From AI to Value - How Data and AI can unlock —
January Cookson value-based care models
11 30th Grace Next steps for tackling antimicrobial resistance London — The presentation overviewed the 75
January Hampson critical priorities and next steps outlined in the
Confronting Antimicrobial Resistance: 2024 to
2029 Policy Paper and discussed solutions to
tackle AMR, including:
12 24th Mikel 39th workshop of Eurordis Roundtable with Brussels, Belgium — Achieving sustainable rare 60
Februar Berdud Companies disease medicine markets for the common
y good? (it was the keynote presentation of a
panel entitled ‘Bridging the gap’: strengthening
European healthcare systems for equitable
patient access)
13 6th Grace AMR conference Basel, Switzerland — Towards an EU multi- 150
Februar Hampson country PULL mechanism Pull incentives for
y new antibiotics
14 s: Mireia The Economics of Healthcare in an Ageing Madrid, Spain — The course was a set of 30
26th- Jofre- Society: A Global Comparison seminars addressing the major policy challenges
28th Bonet for governments and the private sector in the
Februar provision of adequate healthcare systems and
y medicine in a society that continues to live
longer. It outlined global trends in health care,
drawing on economic analysis to provide an
understanding of the complex nature of
healthcare resource allocation, healthcare policy
design and implementation, public and private
healthcare provision as well as why data is
increasingly important in setting policy for
healthcare.
15 28th Amanda More Than You Can Imagine: Genomics and Virtual — Patient Perspective 120
Februar Cole Rare Disease
y
16 Lotte World Evidence, Pricing and Congress 2025 Amsterdam — The UK subscription model for 75
Steuten antimicrobials: what’s next internationally?
17 11th Nadine EuroQol 5th Early Career Researcher Meeting Barcelona, Spain — Conceptualising bolt-ons: 30
March Henderso key questions for their development and use
n
18 11th Sian EuroQoL ECR Meeting Barcelona — Qualitative development of 40
March Hodgson candidate items for a hearing bolt-on for the
EQ-5D-5L
19 12th Chris EuroQol Academy Meeting Barcelona — Bolt-on development: mixed- —
March Sampson methods research programme for cognition,
vision, and hearing
2 13 Lotte FIP Global Vaccination Summit The Hague, Netherlands. — Global challenges 250
0 March Steuten in vaccination from 2025 to 2030: Is pharmacy

----- Start of picture text -----
46
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
part of the solution? Economic value of
vaccines, funding models”
21 20th Amanda Global Payer Forum (Webinar 3: Will a Focus on Virtual 230
March Cole Value Drive the Future of our Healthcare
Systems?
22 20th Patricia London Health Economics Group (LHEG) ABPI-OHE ofces — Development of a 35
March Cubi- meeting synthetic index of primary care output in
Molla England: a feasibility study
2 26th Chris Progress Educational Trust Online — “Is Fertility Treatment A Solution To —
3 March Skedgel Population Decline?”
24 27th Martina Sanof Rare Forum Sanof ofce in Boston — Rarity in value 60
March Garau assessments
2 27th Chris NICE Conference Manchester — Methods and processes that 150
5 March Sampson keep pace with change
2 9th Lotte LSE Market Access Academy Outcomes-Based Payment Models: if not now, 40
6 April Steuten then when?
27 15th Charlotte Abu Dhabi Global Health Week Abu Dhabi, UAE — Building Data Driven 60
April Ashton Healthcare Systems
2 16th Charlotte Abu Dhabi Global Health Week Abu Dhabi, UAE — Personalised Medicine, 80
8 April Ashton Population Health and the Preventative Agenda:
Who Pays the Bill?
2 28th Patricia Seminar at the University of Pablo Olavide Faculty of Economics, Savilla, Spain — “From 25
9 April Cubi- Discount Rates to Patient Voices: Exploring
Molla Methodological Evolution in Health Technology
Assessment Globally“
3 1st May Charlotte Understanding research impact with BMJ of presentation From Research to Impact: The 165
0 Ashton Impact Analytics: Tracking the real-world impact
Infuence of Health Economics Around the
of medical and health research World’
31 8th Simon Adult Immunisation Board Warsaw — Vaccine impact assessment and —
May Brassel economic value of vaccination in aging adults
3 14th Graham ISPOR Montreal 2025 Montreal, Canada — Plenary Session: Drug 50
2 May Cookson Price Controls—What Are the Unintended
Consequences to Innovation?
3 14th Grace ISPOR Montreal 2025 Montreal, Canada — New Approaches to 50
3 May Hampson Sustainable Healthcare: How Can Environmental
Impact Data Contribute to Whole Health?”
3 14th Lotte ISPOR Montreal 2025 Montreal, Canada — Introducing HEMA: An —
4 May Steuten International Working Group for Principled
Assessment of Novel HTA Methods and
Processes
3 15th Lotte ISPOR Montreal 2025 Montreal, Canada — The Value Flower: Evolving —
5 May 14 Steuten the Framework for Comprehensive Value
(moderato Assessment”
r)

----- Start of picture text -----
47
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
3 15th Lotte ISPOR Montreal 2025 Montreal, Canada — “Understanding and —
6 May 14 Steuten Rewarding the Full Value of Long-Acting Session
(moderato Overview
r)
37 16. May Matthias ISPOR Montreal 2025 Montreal, Canada — Novel value elements: —
Hofer Developing and applying a pragmatic value
framework in early stages of product
development [Poster]
3 19 May Martina LSE market access academy LSE, London — Navigating change: 40
8 Garau understanding HTA reforms and other factors
impacting the future of HTA
3 May Mireia American-European Health Economics Study Department of Economics, Oxford University —
50
9 28th Jofre- Group - IX Edition Biosimilars and Price Competition in US
Bonet Pharmaceutical Markets
4 5th Amanda Westminster Health Forum policy conference: Virtual — The importance of early detection, —
0 June Cole Priorities for rare disease diagnosis, care and diagnosis and care coordination
treatment in England
41 9th Mikel Access Forum US 2025 AT&T Executive Conference Center, Austin, 16
June Berdud Texas, US Presentation Title: Unlocking the full
value of biosimilars: Policy challenges and
solutions to market sustainability — Unlocking
the full value of biosimilars: Policy challenges
and solutions to market sustainability
4 9th. Matthias HiPrix Consortium meeting Lisbon — Interim results and progress on OHE 30
2 and 10. Hofer contribution to HiPrix project
June
4 16th Martina HTAi meeting Buenos Aires — Evidence Assessment —
3 June Garau Frameworks and Economic Modelling in Rare
Diseases: A Stakeholder Survey Exploring
Current Practices in HTA
4 17th Mikel XLIV Jornadas de Economía de la Salud of the Universidad Complutense, Madrid, Spain — 21
4 June Berdud Spanish Health Economics Association (AES). Pathways for innovation and sustainability in the
Preconference workshop. development and access to new medicines:
alternative payment schemes and other courses
of action.
4 17th Martina HTAi meeting Buenos Aires — HTAi Rare Disease Interest 50
5 June Garau Group (RDIG): Overview of the group’s
activities and fndings from a survey.
4 17-19 Charlotte Global Sustainable Development Congress Istanbul — Co-chairs of health and wellbeing 100
6 June Ashton 2025 track
and Grace
Hampson
47 17-19 Charlotte Global Sustainable Development Congress Istanbul — Health Economics: The missing link 100
June Ashton 2025 in sustainable development at the Global
and Grace Sustainable Development Congress 2025,
Hampson What was your presentation about? Integrating
health economics into broader development
strategies to ensure long-term impact and
sustainability.

----- Start of picture text -----
48
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
4 7 June Lotte Colloquium at the French Ministry of Health Virtual — The socio-economic value of adult 100
8 Steuten vaccination programmes
4 17th David ISPOR Webinar Online/Virtual — Designing DCEs to Estimate 120
9 June Mott Utilities
5 30th David Pre-HESG Educational Session “Introducing an Brighton — Developments in health valuation & 50
0 June Mott EQ-5D-5L value set for the UK“ the UK EQ-5D-Y-3L
51 18th Simon AES 2025 Madrid — The Socioeconomic Value of Adult —
June Brassel Immunisation
52 19th Mikel XLIV Jornadas de Economía de la Salud of the Universidad Complutense, Madrid, Spain — 120
June Berdud Spanish Health Economics Association (AES). New payment and pricing models for innovation
Panel discussion. and sustainability in pharmaceutical markets.
5 19th Mikel XLIV Jornadas de Economía de la Salud of the Universidad Complutense, Madrid, Spain — 30
3 June Berdud Spanish Health Economics Association (AES). Unlocking Access: Overcoming Barriers and
Oral presentation. Harnessing Enablers for Innovative Payment
Models for Pharmaceutical Innovation in Europe.
5 20th Mikel XLIV Jornadas de Economía de la Salud of the Universidad Complutense, Madrid, Spain — 25
4 June Berdud Spanish Health Economics Association (AES). Implementation Costs and Benefts of
Oral presentation. Innovative Payment Models: an assessment of
four case studies in Europe
5 25 June Grace Breaking Financial Barriers: Sustainable Online — Breaking Financial Barriers: —
5 Hampson Healthcare Financing for RTRS Patients Sustainable Healthcare Financing for RTRS
Patients
5 30th Nadine HESG Summer 2025 Doubletree Hilton, Brighton — Discussion of 30
6 June Henderso “Value of investment in cycleways as a means to
n improve population physical activity and
alleviate inequalities“
57 30 June Sian HESG Brighton — Heterogeneous efects of primary —
Hodgson care funding on access to care: A longitudinal
(as study of English general practice, 2014-2022
Discussan
t), Hannah
Hussain -
as chair
5 1st July Matthew HESG Brighton — Discussion of: A systematic review —
8 Napier of using SROI on investment within healthcare
service evaluations: Methodological
opportunities and challenges
5 1st July Chris HESG summer 2025 Brighton, UK — Discussion of ‘Identifying key 25
9 Sampson patient characteristics for the
acknowledgement of patient heterogeneity in
economic evaluations in severe mental illness’
6 1st July Sian HESG Summer 2025 Brighton — Heterogeneous efects of primary —
0 Hodgson care funding on access to

----- Start of picture text -----
49
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
61 1st July Sian HESG Summer 2025 Brighton — Hospital Ownership and Quality: A —
Hodgson Decomposition Analysis Using Process and
Outcome Indicators
6 2nd July Event: HESG summer meeting Brighton, UK — Methods for the Economic —
2 HESG Evaluation of Health Impacts of Climate Action:
summer When, Why, and How Best to Use Them? A
meeting Literature Review.
6 2nd July Mireia HESG Summer 2025 Brighton — Building a synthetic population to —
3 Jofre- assess the health impacts of local climate
Bonet change policies in England.
6 1st July Amanda HESG Brighton — Early Career Researcher session —
4 Cole “Health Economics Career Paths: The Good, the
Bad and the Ugly“
6 2nd July Amanda HESG Brighton — The ‘Canberra Hypothesis’ 50 years —
5 Cole on: medicine prices and the economics of the
pharmaceutical industry
6 4th July Chris CERSI PGx Workshop Online — An approach to estimating the value —
6 Sampson of pharmacogenomics to the UK Economy
67 17 July Patricia NICE Technical Forum - Seminar online — Navigating change: a comparative —
Cubi- analysis of Health Technology Assessment
Molla reforms across agencies and their
interdependencies.
6 21. July Matthias IHEA Location: Bali Bali — Implementation costs and benefts of 40
8 Hofer innovative payment models
Event:
IHEA
Location:
Bali
6 21. July Matthias IHEA Bali — How to incorporate a societal —
9 Hofer perspective in Asia-Pacifc decision making?
Event: What was your presentation about?
IHEA Characterisation of the status quo and ways to
foster the consideration of a societal
perspective in HTA decision making in Asia-
Pacifc countries. Part of the BRAVER
consultancy project.
70 21. July Matthias IHEA Bali Presentation Title: Overcoming barriers and —
Present Hofer harnessing enablers for innovative payment
er: Event: models for pharmaceutical innovation in Europe
Matthia IHEA — Overcoming barriers and harnessing
s Hofer enablers for innovative payment models for
Event: pharmaceutical innovation in Europe
IHEA
71 21st Chris IHEA 2025 Bali, Indonesia — Decision Analysis for —
July Sampson Planetary and Human Health: Waste
Management in the Life Sciences Industry
72 23rd Mireia IHEA 2025 Bali, Indonesia — Guideline Development: More
—
July Jofre- Than Just Another Checklist
Bonet

----- Start of picture text -----
50
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
73 23rd Mireia IHEA Bali, Indonesia — Methods for the Economic —
July Jofre- Evaluation of Health Impacts of Climate Action:
Bonet When, Why, and How Best to Use Them? A
Literature Review
74 11th Hannah Health Economics for Policy Research Seminar Virtual — Enhancing health-related quality of —
Septem Hussain Series life (HRQoL) assessment for economic
ber evaluation in dementia populations
75 18th Chris Inaugural Resource Allocation Symposium Birmingham, UK — Forecasting the value of a 80
Septem Sampson system-shift in health and social care: making a
ber case for investment with economic evaluation
76 22nd Patricia X Programa Experto en Politica Sanitaria y Palma de Mallorca — Competencia, regulación —
Septem Cubi- Farmacoeconomia: es más siempre mejor? y gasto: ¿siempre mas es mejor? Visión
ber Molla internacional
77 24th Chris Concordia Summit, NYC “How to fnd national cardiovascular health —
Septem Skedgel action plans“
ber
78 25th Chris 42nd EuroQol Plenary Vienna, Austria — Discussion of ‘Comparison of
—
Septem Sampson the EQ-5D-5L cognition bolt-on and EQ-HWB
ber cognition dimensions: Results from EQ-
DAPHNIE data in China and Japan
79 24th Chris Concordia Summit, NYC “How to fnd national cardiovascular health —
Septem Skedgel action plans“
ber
8 25th Chris 42nd EuroQol Plenary Vienna, Austria —
0 Septem Sampson
ber
81 1st Grace Rising to the Challenge: Utilizing Diagnostics to Geneva — Taking STRIDES: The value of —
Octobe Hampson Combat Infectious Diseases and AMR diagnostics against AMR
r
8 1st Lotte GAMRIC Conference London: — Taking Strides: The value of —
2 Octobe Steuten diagnostics against AMR
r
8 1st Martina CIRS meeting London —
3 Octobe Garau
r
8 7th Lotte Roundtable The Unseen Burden of Migraine: , Paris — Roundtable participant: Lotte was —
4 Octobe Steuten Impacts on Care, Productivity, and Economic invited to a private roundtable, which was
r Growth in an Aging Society. organized with funding from Pfzer, conveneing
leaders from across sectors and disciplines to
explore migraine’s multi-faceted impact on
healthcare systems, workplace productivity and
economic growth, quality of life, and caregiving
in a rapidly aging world. The interactive
discussions aim was to identify impactful
solutions and policy actions to ensure that
those afected by migraine receive the attention
and care needed.

----- Start of picture text -----
51
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
8 8th Lotte Building healthy, productive workforces for our Paris — Lotte was invited to provide health 30
5 Octobe Steuten 21st century Closed doors meeting, hosted by economics insights on the value of prevention
r OECD and the Global Coalition on Aging
8 8th Lotte Pfzer’s Adult Vaccine-Preventable Respiratory Virtual — Health system impacts of vaccine 35
6 Octobe Steuten Disease (VPRD) Advisory Panel session uptake and broader socio-economic value of
r adult vaccination
87 12th Lotte Title: World Health Summit Berlin — World Health Summit —
Octobe Steuten
r
8 14th Chris “Severity Matters“ Forum Online — “The NICE Severity Modifer and 12
8 Octobe Skedgel Public Preferences around Severity“
r
8 15th Helen EACS Paris 2025: —
9 Octobe Hayes
r
9 15th Lotte World Vaccine Congress Europe 2025 Amsterdam, The Netherlands — Lotte 200
0 Octobe Steuten moderated a session on the importance of and
r methodologies for evaluating the broader value
of vaccines
91 18th Simon Global Infuenza Initiative (GII)- Annual Meeting Valencia —
Octobe Brassel Location: Valencia
r
9 21st Lotte GSK/ViiV Healthcare Preventing the Cost of London — This event – sponsored by GSK and —
2 Octobe Steuten Inaction policy roundtable discussion ViiV Healthcare in partnership with the Terrence
r Higgins Trust, and co-hosted by Baroness
Ritchie & Richard Angell, CEO Terrance Higgins
Trust – brought together parliamentarians,
ofcials, patient groups and experts to explore
how we can move from ambition to action in
embedding a prevention-frst ethos across the
health system. Lotte used this opportunity to
share experiences, surface practical solutions
and identifed where collective action can make
the greatest diference.
9 22nd Lotte SMDM Virtual Course: Handling Uncertainty in Online — Interpret and report results of 27
3 Octobe Steuten HTA Processes uncertainty analyses for HTA.
r
9 28th Lotte World Orphan Drug Congress 2025 Amsterdam — Panel title: Expanding patient 80
4 Octobe Steuten access to multi-indication medicines in Europe
r through innovative agreements
9 10th Lotte ISPOR Europe 2025 Glasgow, UK — “Integrating Capacity- —
5 Novem Steuten Enhancing Innovations in Healthcare Systems:
ber Are Current Methods Adequate to Demonstrate
the Impact on Efciency and Capacity?”
9 6th Simon European Policy Center Roundtable Brussels —
6 Novem Brassel
ber

----- Start of picture text -----
52
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
97 10th Mikel ISPOR Europe 2025 Glasgow, UK —
Novem Berdud
ber
9 11th Lotte ISPOR Europe 2025 Glasgow, UK — More Than a Long Shot: 250
8 Novem Steuten Rethinking the ROI of Modern Medicines for
ber and David Public Health
Mott
9 11th Lotte ISPOR Europe 2025 Glasgow, UK — Can We Have It “Whole”? 80
9 Novem Steuten Barriers and Opportunities for Embracing a
ber and Simon Whole Health Perspective in HEOR
Brassel
10 11th Sian ISPOR Europe 2025 Glasgow, UK —
0 Novem Hodgson
ber
10 11th Mireia ISPOR Europe 2025 Glasgow, UK — The ECOnomiC Valuation of 50
1 Novem Jofre- the Health Impacts of Climate Action (or
ber Bonnet Inaction): The ECO-CHICA Guidelines
10 11th Grace ISPOR Europe 2025 Glasgow, UK — Adding Nature’s Petal to the —
2 Novem Hampson Value Flower: Can Inclusion of Environmental
ber Impact in HTA Aid the Race to Net Zero?
10 11th Graham ISPOR Europe 2025 Glasgow, UK — Increasing Transparency of —
3 Novem Cookson Public Funding in Pharmaceutical Research and
ber Development Reporting
10 11th Martina ISPOR Europe 2025 Glasgow, UK — A Systematic Review of 60
4 Novem Garau Economic Modeling Challenges and Proposed
ber Solutions for Rare Disease Technologies: An
HTAi RDIG Initiative
10 11th Mikel ISPOR Europe 2025 Glasgow, UK — How Can We Make Innovative 240
5 Novem Berdud Payment And Pricing Schemes a “Win” From All
ber Perspectives?
10 11th George ISPOR Europe 2025 Glasgow, UK — Science At PACE? A multi- —
6 Novem Bray stakeholder developed framework for
ber Accelerated Patient Access to Cancer Care
10 11th Grace ISPOR Europe 2025 Glasgow, UK — Novel Antibiotic Value Elements 10
7 Novem Hampson in the Context of Antimicrobial Resistance
ber RECOGNISING THE VALUE OF NOVEL
ANTIBIOTICS
10 12th Helen ISPOR Europe 2025 Glasgow, UK — The Cost of Complacency: 10
8 Novem Hayes Projecting the Burden of HIV Care in Eight
ber European Countries
10 12th Brittany ISPOR Europe 2025 Glasgow, UK — Overcoming Barriers and 10
9 Novem Darrow Harnessing Enablers for Innovative Payment
ber Models for Pharmaceutical Innovation in Europe.
11 12th George ISPOR Europe 2025 Glasgow, UK — Fiscal Health modelling of C19 10
0 Novem Bray in the UK.
ber

----- Start of picture text -----
53
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

# DATE PRESENT EVENT LOCATION / TITLE AUDIE
ER NCE
111 12th Hania El ISPOR Europe 2025 Glasgow, UK — The Enduring Economic Burden 10
Novem Banhawi of COVID-19 and the Value of Vaccination
ber Strategies in High-Income Countries.
11 12th Matthew ISPOR Europe 2025 Glasgow, UK — The Socioeconomic Value of 20
2 Novem Napier Adult Respiratory Immunization Programs in
ber Spain: How Much Can We Gain From Expanding
Prevention Eforts?
11 12th Martina ISPOR Europe 2025 Glasgow, UK — Science at PACE? A 30
3 Novem Garau Multistakeholder Developed Framework for
ber Accelerated Patient Access to Cancer Care
11 12th David ISPOR Glasgow —
4 Novem Mott
ber
11 13th Chris National Pharmacogenomics and Medicines Manchester 120
5 Novem Sampson Optimisation Network of Excellence event
ber
11 18th Lotte TASPOR Annual Meeting 2025 Taiwan (virtual) — UK Approaches to Cancer 356
6 Novem Steuten Combination Therapy Reimbursement and
ber Emerging Value Attribution Frameworks: Lessons
from the UK and the EU
11 18th Lotte World Antimicrobial Resistance Week (WAAW) Geneva - virtual — The Global Value of 821
7 Novem Steuten 2025 Diagnostics: Stewardship and Appropriate Use,
ber the Broader Healthcare System, and Beyond
11
8
11th
Novem
ber
Mireia
Jofre-
Bonnet
ISPOR Europe 2025 Glasgow, UK — Methods for the Economic
Evaluation of Health Impacts of Climate Action.
A Scoping Review.
20
11 13th Mikel Lecture at City, St Georges University of London 22
9 Novem Berdud London
ber
12 11th Mireia Invited guest lecture for the Executive MSc LSE Campus, London 50
0 Decem Jofre- Programme in Health Policy, Department of
ber Bonet Health Policy, LSE
12 3rd Lotte Healthcare’s Competitive Future: From Reactive Paris, France 300
1 Decem Steuten Systems to Economic Catalysts (by Business at
ber OECD Health Forum)
12 5th Simon British Embassy Event Riga Riga 25
2 Decem Brassel
ber

----- Start of picture text -----
54
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Appendix D — OHE staff membership of advisory panels, boards and committees

Advisory Panels

Health Foundation

HTAi

CIRS

NHS England

NIHR

Other advisory boards

Scientific Committees

Interest Groups/Task Forces

Clinton Foundation Global Initiative

Women in Global Health - UK Chapter

IHEA

----- Start of picture text -----
55
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

ISPOR

EuroQol

HTAi

Editorial Roles

Value in Health

Applied Health Economics and Health Policy Journal

PharmacoEconomics

Orphanet journal of rare diseases

Patient Preference and Adherence

Grant Panel Advisory Groups

NICE

NIHR

Novartis/Spanish Health Economics Association (AES)

• Panel for the research grant “Becas de investigacion en Economia de la Salud”, awarded by the Spanish Health Economics Association (AES), funder: Novartis – Patricia Cubi-Molla

“La Caixa” Foundation

Visiting Positions for OHE Staff

City St George’s, University of London

----- Start of picture text -----
56
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Fred Hutch Cancer Research Center, University of Washington

Public University of Navarra

University of East Anglia

University of Surrey

School of Medicine, University of Nottingham

Memberships

Many OHE researchers are also members of associations such as ISPOR, IHEA, HESG, AES, EuroQoL ,,and iHTA .

----- Start of picture text -----
57
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

Appendix E— Funding in 2025

Projects won in 2025

FUNDER
EUROPEAN
COMMISSION
EUROPEAN
COMMISSION
THE UNIVERSITY OF
SUSSEX
UNIVERSITY OF
MANCHESTER
INNOVATE UK
NESTA
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
NATIONAL INSTITUTES
OF HEALTH
CML ADVOCATES
NETWORK
EUROQOL RESEARCH
OXYGEN STRATEGY
TOTAL
Project Title
Theme
Year won
Project
Budget
TEN4CARE
VADM
Sep-25
£306,544
PREDICT FTD
VADM
Jan-25
£263,512
Green Healthcare Hub Decarbonising
H&SC)
POIHS
Oct-25
£213,455
CEiRSI Economic Impact In Silico
EoI
Jul-25
£124,994
CERSI-PGx Value of pharmacogenomics to
the UK
VADM
Jan-25
£79,932
Commercial Case for ALS
EoI
Jul-25
£39,996
Does a spoonful of honey improve a barrel
of tar? 33333 vs 33333+1
MVO
Oct-25
£23,752
Assessing bolt-ons in cognition (ABC)
MVO
Jan-25
£21,962
ModEx advisory panel
VADM
Jan-25
£10,000
Extension of CML patient preference study
MVO
Aug-25
£9,713
OPUF bolt-on valuation
MVO
Sept-25
£3,995
Severity Matters Roundtable
MVO
Oct-25
£2,000
£1,099,805

*Networks built through previous European projects continued to pay dividends: in 2025 OHE secured a further HORIZON grant (TEN4CARE) and submitted further applications.

Projects won before 2025 and still live

FUNDER
CML ADVOCATES
NETWORK
EUROPEAN
COMMISSION
ACUTE LEUKAEMIA
ADVOCATES NETWORK
LONDON SCHOOL OF
HYGIENE & TROPICAL
MEDICINE
ACUTE LEUKAEMIA
ADVOCATES NETWORK
ACUTE LEUKAEMIA
ADVOCATES NETWORK
Project Title
Theme
Year won
Project
Budget
CML patient preference study
MVO
Jul-24
£377,578
EU HORIZON HIGH-PRIX
EoI
Mar-23
£354,263
Patient preferences for Leukaemia
treatments: UK/US/EU4 1L all phases
MVO
Nov-23
£210,477
ECO-CHICA Valuing the Health Impact of
Climate Actions
MVO
Dec-24
£156,284
Acute Leukaemia carer preference study
MVO
Nov-23
£149,876
Patient preferences for Leukaemia
treatments: US/EU4 R/R all phases
MVO
Jan-23
£105,117

----- Start of picture text -----
58
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

FUNDER
EUROQOL RESEARCH
FOUNDATION
ACUTE LEUKAEMIA
ADVOCATES NETWORK
HIGH FLOW THERAPY UK
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
TOTAL
Project Title
Theme
Year won
Project
Budget
Development and testing of a hearing bolt-
on
MVO
Jan-21
£77,456
Patient preferences for Leukaemia
treatments: UK R/R phases 5
MVO
Jun-23
£73,789

High Flow Therapy Post AECOPD
VADM
Oct-24
£71,159
Exploring the use of the OPUF tool for
valuing EQ-5D Y 3L
MVO
Jan-22
£63,310
EQ-5D Bolt-on Development
MVO
Jan-19
£57,700
Bolt-on Conceptual
MVO
Sep-23
£32,599
Estimating an EQ-5D-Y-3L set in the United
Kingdom
MVO
Jul-23
£7,650
£1,739,226

Projects won before 2025 and closed during 2025

FUNDER
IFPMA
THE HEALTH
FOUNDATION
AMICUS THERAPEUTICS
CURTA, INC
PARKINSON’S UK
IFPMA
UCL
TOTAL
Project Title
Theme
Year won
Project
Budget
Socio-economic value of adult vaccination
VADM
Dec-22
£467,373
Efciency and Labour Productivity in Primary
Care
POIHS
Mar-21
£410,325

Diversity of supply for rare disease
medicines
EoI
Oct-24
£84,513
Biosimilar Market Dynamics: A Review and
Simulation Model
EoI
Jun-23
£23,650
PwP Mindfulness app
VADM
Sep-21
£15,318
Extension of Socio-economic value of adult
vaccination Flu Abstract
VADM
Apr-24
£2,598
UCL Health Exec Ed Program
EoI
Nov-24
£1,969
£1,005,745

Grant and project pipeline at year end

FUNDER
EUROPEAN COMMISSION
EUROPEAN COMMISSION
NIHR
EUROPEAN COMMISSION
EUROPEAN COMMISSION
EUROPEAN COMMISSION
THE FLEMING INITIATIVE
Project Title
Value
Probability %
Proj. Adj.
Value
PHAGE4EYE
£323,296
10
£32,330
SMARTCell
£305,790
10
£30,579
Expected Value of Environmental
Information
£295,000
15
£44,250
FARM2FORM
£280,000
20
£56,000
CAT Shine
£233,333
5
£11,667
NANOPANTHER
£208,333
5
£10,417
AMR Strategic Policy TFI
£150,000
50
£75,000

----- Start of picture text -----
59
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

FUNDER
CHANGE INITIATIVE -
COMPANY PARTNERSHIP
QUEEN MARY UNIVERSITY OF
LONDON
ACUTE LEUKAEMIA
ADVOCATES NETWORK
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
EUROPEAN COMMISSION
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
EUROQOL RESEARCH
FOUNDATION
NIHR
VERIAN
EUROQOL RESEARCH
FOUNDATION
NIHR
EUROPEAN COMMISSION
NIHR
TOTAL
Project Title
Value
Probability %
Proj. Adj.
Value
Policy Horizons (US) - Change Initiative
£148,350
100
£148,350
Modelling AMR Dx
£136,000
5
£6,800
Creating Opportunities to Hear the
Patient Voice
£100,056
35
£35,020
Sleep bolt-on development
£8,216
100
£8,216
Hearing bolt-on in bilateral cochlear
implants
£2,822
100
£2,822
Cognition bolt-on in stroke in HK
£2,813
100
£2,813
Cognition bolt-on Hong Kong
£2,254
100
£2,254
DG SANTE framework bid
£0
15
£0
Cognition bolt-on qual analysis
£0
70
£0
Hearing bolt-on implants Belgium
£0
20
£0
Vision bolt-ons in diabetic retinopathy
£0
20
£0
2025/400 i4i FAST NeuroSpeechAI
£0
100
£0
DG Grow - supply chains and business
intelligence services
£0
10
£0
Swallowing and communication bolt-on
development
£0
5
£0
Adult social care research capacity
£0
5
£0
EU HORIZON Green Healthcare
£0
5
£0
HEAT-CARE
£0
5
£0
£2,196,263
£466,518

Unsuccessful proposals, 2025

FUNDER
NATIONAL INSTITUTE FOR HEALTH
RESEARCH (NIHR)
WELLCOME TRUST
NATIONAL INSTITUTE FOR HEALTH
RESEARCH (NIHR)
SCIENCE FOR AFRICA
WELLCOME TRUST
UKRI
NATIONAL INSTITUTE FOR HEALTH
RESEARCH (NIHR)
Project Title
Theme
Value
NIHR Global LMICs Partnership AMPATH
POIHS
£494,213
AIIG Climate Impact Award
POIHS
£485,438
NIHR Global LMICs Partnership AIIG
POIHS
£477,750
EPSILON
POIHS
£299,000
Climate Impact Award
POIHS
£250,000
Decarbonising H&SC - Scottish Consortium
POIHS
£190,000
NIHR C2-Ai
POIHS
£175,350

----- Start of picture text -----
60
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

FUNDER
PHYSICIANS COMMITTEE FOR
RESPONSIBLE MEDICINE
NATIONAL INSTITUTE FOR HEALTH
RESEARCH (NIHR)
EUROQOL RESEARCH FOUNDATION
NATIONAL INSTITUTE FOR HEALTH
RESEARCH (NIHR)
ASTELLAS PHARMA US INC
TOTAL
Project Title
Theme
Value
US impact of vegan diets
POIHS
£136,821
NIHR RfPB - PACT PwP
VADM
£42,500
Communication and swallowing bolt-on
development
MVO
£0
NIHR Health Kiosks Evaluation
POIHS
£0
Combination therapies legal frameworks
EoI
£0
£2,551,071

----- Start of picture text -----
61
----- End of picture text -----

ohe.org

OFFICE OF HEALTH ECONOMICS ANNUAL CHARITY REPORT

About us

With over 60 years of expertise, the Office of Health Economics (OHE) is the world’s oldest independent health economics research organisation. Every day we work to improve health care through pioneering and innovative research, analysis, and education.

As a global thought leader and publisher in the economics of health, health care, and life sciences, we partner with Universities, Government, health systems and the pharmaceutical industry to research and respond to global health challenges.

As a government-recognised Independent Research Organisation and not-for-profit, our international reputation for the quality and independence of our research is at the forefront of all we do. OHE provides independent and pioneering resources, research and analyses in health economics, health policy and health statistics. Our work informs decision-making about health care and pharmaceutical issues at a global level.

All of our work is available for free online at www.ohe.org .

ohe.org

The Office of Health Economics A Company Limited by Guarantee of Registered No.09848965 OHE Consulting Ltd Registered Company No.09853113 OHE is a Charity Registration No.1170829 ohe.org Registered Office 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB

62

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

Registered number: 09848965 Charity number: 1170829

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2025

Trustees Ms A R Charlesworth, Trustee
Dr R D Torbett, Trustee
Mr W P Holmes, Trustee
Mr W B F Brouwer, Trustee
Mr P Catchpole, Trustee (resigned 13 November 2025)
Mr T E Allvin, Trustee
Ms R Tarricone, Trustee (appointed 20 May 2025)
Ms V Jordan, Trustee (appointed 1 December 2025)
Company registered
number
09848965
Charity registered
number
1170829
Registered office
2nd Floor Goldings House
Hay's Galleria
2 Hay's Lane
London
SE1 2HB
Company secretary
R Hollingsworth
Chief executive officer
Prof G Cookson
Independent auditor
BDO LLP
55 Baker Street
London
United Kingdom
W1U 7EU
Bankers
National Westminster Bank Plc
PO Box 414
38 Strand
London
WC2H 5JB

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

CONTENTS
Page
Trustees' Report 1 - 7
Independent Auditor's Report 8 - 13
Consolidated Statement of Financial Activities 14
Consolidated Balance Sheet 15
Company Balance Sheet 16 - 17
Consolidated Statement of Cash Flows 18
Notes to the Financial Statements 19 - 32

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

The Trustees, who are also directors for the purposes of company law, present their report together with the audited consolidated financial statements of the group and the company, ‘The Office of Health Economics’ ("OHE", "the charitable company", "the charity" or "the company") (charity number 1170829) (registered in England and Wales), and its subsidiary undertaking OHE Consulting Limited (registered in England and Wales) (collectively "the group") for year ended 31 December 2025.

The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019.

As stated in Note 19 to the financial statements the ultimate parent company of OHE is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"). The registered address of the ABPI is 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB. The ABPI provides a research grant to OHE to enable it to independently progress its charitable purpose and objectives as summarised below.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019 ("Charities SORP FRS 102").

Objectives and activities

The Office of Health Economics’ objectives are to advance the education of the public in general/health care payers/policy makers, particularly patients and healthcare professionals, on the subject of health economics and healthcare policy.

Activities in furtherance of this include, in particular, but not exclusively:

The term "health economics" means the application of economic theory, models and empirical techniques to the analysis of decisions making by people, health care providers and governments with respect to health and health care.

In planning the activities of the charity, the Trustees have had regard to the Charity Commission's guidance on public benefit. They consider the information which follows in this annual report, about the company's aims, activities and achievements in the areas of interest that the company supports demonstrates the benefit to its beneficiaries and through them to the public.

Page 1

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Achievements and performance

OHE has once again undertaken an ambitious programme of original research, generating findings published in high quality peer reviewed journals, and via its own publication series, on the economics of health technology appraisal, the economics of health care systems and the economics of the life sciences industry. OHE’s work has direct relevance to policy, and evidence from our research programme informs health care decision making and health care policy. OHE also contributes directly to the development and promotion of excellence in the field of health economics via our seminars, lectures, leadership roles in professional societies, and other academic activities. OHE’s consulting arm has produced authoritative analyses for our clients and a financial surplus from which it contributes to the financial sustainability of OHE as a research charity.

The company and group have continued to perform successfully this year. Internal and external funding has continued to be provided to finance a wide range of research projects and consultancy advice provided to the life sciences industry, public sector organisations and the ABPI.

The key performance indicators are external research funding targets, consultancy income targets and operating expenditure targets. In 2025, research funding was 105% of target and consultancy income was 115% of target.Consultancy income grew 5% compared to the previous year whilst research funding grew 18%. Operating expenditure in 2025 was 103% of the budget target. Overall, the company made a net operating loss, before receipt of Gift Aid from OHE Consulting Limited, as it made significant investments in charitable work. However, overall the group reported a strong surplus of more than 340% of target which has enabled it to reach its reserves target.

Financial review

a. Going concern

After making appropriate enquiries, and getting confirmation of on going support from ABPI (Note 18), the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

The Trustees are aware that the operational and financial implications of the various conflict in the world, have been considered by the Governance Committee of OHE’s ultimate parent company the ABPI. The Governance Committee have concluded that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements.

Page 2

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Financial review (continued)

b. Reserves policy

The Trustees have examined the charitable company's requirement for resources in light of the main risks to the company and have no outstanding commitments or cash demand which are not adequately covered by existing resources.

The group’s reserves policy continues to ensure that the company has adequate cash and reserves to meet current and future needs, and this is reviewed annually as part of the budget process. The charity reserves were £2,024,129 (2024 - £1,567,558 ) as at the year ended 31 December 2025.

The group's reserves target is 6 months of payroll expenditure. For 2026, that would be a target of £1,994,802 which has now been met. The Trustees and Executive Management will review the Reserves Policy this year whilst continuing to target a 5% surplus. We suggest that generating a surplus which is too significant would not be in accordance with delivering on our Charitable Objects.

The policy will seek to balance the goal of sustainability with the needs to be efficient as a not-for-profit organisation. Research funding and consultancy contracts are always agreed before making any expenditure commitments.

c. Work programmes and funding

The company's current work programme is supported by research grants and consultancy revenues from a wide range of UK and international sources including the ABPI and other commercial clients, as well as government agencies, European Commission, and a number of charitable and other organisations.

d. Results for the year

OHE Consulting Limited, the company's wholly owned subsidiary, made an operating profit of £1,119,472 (2024 - £1,614,938) and made a qualifying charitable donation via Gift Aid for this amount to its parent company, the OHE.

The company made an operating loss of £662,901 (2024 - £1,194,790) prior to the Gift Aid payment received from OHE Consulting Limited, and therefore overall the group realised a profit for 2025 of £456,571 (2024 - profit of £474,894) .

e. Fundraising

Section 162a of the Charities Act 2011 requires charities to make a statement regarding fundraising activities. Although we do not undertake fundraising from the general public, the legislation defines fundraising as "soliciting or otherwise procuring money or other property for charitable purposes." Such amounts receivable would be presented in our accounts as "voluntary income" and includes legacies and grants.

Page 3

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Structure, governance and management

a. Constitution and legal structure

The company is registered as a charitable company limited by guarantee (charity number 1170829) and was set up by a Memorandum of Association on 29 October 2015.

The company has a wholly owned subsidiary, OHE Consulting Limited, a company limited by shares. This company provides health economic consultancy services to the life sciences industry. The legal structure enables the research activities of the charitable company to be kept separate to the commercial consultancy activity. Both companies share the same directors and key management personnel.

b. Methods of appointment or election of Trustees

The management of the company is the responsibility of the Trustees who are elected and co opted under the terms of the Memorandum of Association.

The ABPI, as the sole member of the charity, has the sole right to appoint Trustees to the Board of the charity.

c. Policies adopted for the induction and training of Trustees

As part of their training, Trustees are provided a comprehensive 'operating' manual, which includes the charitable company's Memorandum of Association and Charity Commission guidance on trustee responsibility. All Trustees are aware of their legal duties and obligations in respect of the management of the charitable company, including in relation to the protection of its assets.

d. Pay policy for key management personnel

Two Trustees (2024: Two) received fees for services during the period. Details of Trustees' fees, expenses and related party transactions are disclosed in Note 8 to the financial statements.

The company uses benchmark data from other research and consultancy organisations to help set pay and remuneration for key staff. Annual pay reviews are then linked to performance against agreed objectives, inflation rates and market trends.

Page 4

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Structure, governance and management (continued)

e. Organisational structure and decision-making policies

The company is governed by the Board of Trustees. The Trustees of the company during the period were as follows:

Ms A Charlesworth, Trustee Mr R D Torbett, Trustee Mr W P Holmes, Trustee Mr W B F Brouwer, Trustee Mr P Catchpole, Trustee (resigned 13 November 2025) Mr T E Allvin, Trustee Ms R Tarricone, Trustee (appointed 20 May 2025) Ms V Jordan, Trustee (appointed 1 December 2025)

In addition to the Board of Trustees, the company is managed by the Executive Management Team, and advised by an Editorial Committee, a Research Committee and a Policy Committee. Each Committee is Chaired by a Trustee and provides regular reports to the entire Board.

The Executive Management Team during the period were as follows:

Prof G Cookson (Chief Executive) Prof L Steuten (Deputy Chief Executive) Prof M Jofre Bonet (Chief Research Officer and Head of Education)

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. Transactions with other related parties are disclosed in Note 18.

As per the company Articles, the ABPI is entitled to appoint a majority of the Trustees (4/7), one of which is the Chief Executive of the ABPI.

f. Risk management

The Trustees have assessed the major risks to which the company is exposed, in particular those related to the operations and finances of the company, and are satisfied that systems and procedures are in place to manage the exposure to the major risks. They have also considered the reputational risk of the company and ensure transparency and strong communiaction is carried out with stakeholders.

The principal risks facing the company and group are a reduction in research funding or consultancy income together with the loss of key staff. Funding and income wins and proposals are closely monitored against budget expectations by the Executive Management Team and if necessary cost savings are identified to cover any income shortfall. A competitive remuneration package, development through work experience and succession planning are used to attract and retain high calibre staff.

Page 5

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Plans for future periods

OHE will continue to develop its programme of original research, supported by a wide range of research funders in the UK and internationally. OHE will continue to expand the focus of our work beyond the UK, and to focus effort on maximising the impact of our research on improving health care decision making both in the UK and further afield. In its role as an established charity, OHE will be developing evidence based policy positions, which it will disseminate by engaging with a wide range of stakeholders via events, media commentaries, and publications.

Statement of Trustees' responsibilities

The Trustees (who are also directors of OHE for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial period. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and group for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditor

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that:

Page 6

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Auditor

The auditors, BDO LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). The registered office is 55 Baker Street, London, W1U 7EU.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2016 relating to small companies.

This report was approved by the Trustees, and signed on their behalf by:

Trustee

Trustee

Date: 29-Sep-2026 | 14:07 BST Date: 29-Sep-2026 | 13:23 BST

Page 7

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS

Opinion

In our opinion the financial statements:

We have audited the financial statements of the Office of Health Economics (“the Parent Charitable Company”) and its subsidiaries (“the Group”) for the year ended 31 December 2025 which comprise the following:

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remain independent of the Group and the Parent Charitable Company in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Page 8

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group and the Parent Charitable Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Group and the Parent Charitable Company’s ability to continue as a going concern.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Report and Financial Statements, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Page 9

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Other Companies Act 2006 reporting

In our opinion, based on the work undertaken in the course of the audit:

In the light of the knowledge and understanding of the Group and the Parent Charitable Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion;

Responsibilities of Trustees

As explained more fully in the Statement of Trustees’ responsibilities, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group’s and the Parent Charitable Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations, or have no realistic alternative but to do so.

Page 10

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the Charitable Company and management.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Non-compliance with laws and regulations

Based on:

we considered the significant laws and regulations to be the applicable accounting framework (UK GAAP), Companies Act 2006, Charities Act 2011, and relevant UK tax legislation.

The Group is also subject to laws and regulations where the consequence of non-compliance could have a material effect on the amount or disclosures in the financial statements, for example through the imposition of fines or litigations. We identified such laws and regulations to be employment law, data protection and health and safety legislation.

Our procedures in respect of the above included:

Page 11

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Fraud

We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included:

Based on our risk assessment, we considered the areas most susceptible to fraud to be management override of controls through the posting of inappropriate journal entries and early consultancy and research revenue recognition.

Our procedures in respect of the above included:

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members who were all deemed to have appropriate competence and capabilities and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council’s (“FRC’s”) website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Page 12

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Use of our report

This report is made solely to the Charitable Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charitable Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charitable Company and the Charitable Company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Fiona Condron (Statutory Auditor)

For and on behalf of BDO LLP, Statutory Auditor London, UK

Date: 29 September 2026

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

Page 13

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025

Note
Income from:
Donations and research grant
Charitable activities
Other trading activities
Interest receivable
Total income
Expenditure on:
Costs of other trading activities
4
Charitable activities
4
Total expenditure
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward
Unrestricted
funds
2025
£
302,317
948,358
4,414,549
22,849
5,688,073
3,312,806
1,918,696
5,231,502
456,571
1,567,558
456,571
2,024,129
Total
funds
2025
£
302,317
948,358
4,414,549
22,849
5,688,073
3,312,806
1,918,696
5,231,502
456,571
1,567,558
456,571
2,024,129
Total
funds
2024
£
205,484
855,987
4,204,016
16,745
5,282,232
2,609,887
2,197,451
4,807,338
474,894
1,092,664
474,894
1,567,558

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 19 to 32 form part of these financial statements.

Page 14

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2025

Note
Fixed assets
Tangible assets
9
Current assets
Debtors
10
Cash at bank and in hand
Creditors: amounts falling due within one
year
11
Net current assets
Total assets less current liabilities
Provisions for liabilities
Net assets
Total net assets
Charity funds
Restricted funds
Unrestricted funds
Total funds
2,358,498
3,344,965
5,703,463
(3,478,659)
2025
£
1,325
1,325
2,224,804
2,226,129
(202,000)
2,024,129
2,024,129
-
2,024,129
2,024,129
2,724,920
694,601
3,419,521
(1,869,183)
2024
£
17,220
17,220
1,550,338
1,567,558
-
1,567,558
1,567,558
-
1,567,558
1,567,558

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Trustee Trustee

Date: 29-Sep-2026 | 14:07 BST

Date: 29-Sep-2026 | 13:23 BST

The notes on pages 19 to 32 form part of these financial statements.

Page 15

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET AS AT 31 DECEMBER 2025

Note
Fixed assets
Tangible assets
9
Investments
Current assets
Debtors
10
Cash at bank and in hand
Creditors: amounts falling due within one
year
11
Net current assets
Total net assets less current liabilities
Charity funds
Unrestricted funds
Total funds
3,042,734
1,122,611
4,165,345
(2,142,542)
2025
£
1,325
1
1,326
2,022,803
2,024,129
2,024,129
2,024,129
2,067,875
305,491
2,373,366
(823,029)
2024
£
17,220
1
17,221
1,550,337
1,567,558
1,567,558
1,567,558

Page 16

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2025

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements.

The profit after tax after gift aid of the parent Company for the year was £456,571 (2024 - £474,894) .

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Trustee Trustee

Date: 29-Sep-2026 | 14:07 BST Date: 29-Sep-2026 | 13:23 BST

The notes on pages 19 to 32 form part of these financial statements.

Page 17

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025

Cash flows from operating activities
Net cash generated from operating activities (note 14)
Cash flows from investing activities
Net cash provided by investing activities
Cash flows from financing activities
Interest received
Net cash provided by financing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
The notes on pages 19 to 32 form part of these financial statements
2025
£
2,627,515
-
22,849
22,849
2,650,364
694,601
3,344,965
2024
£
18,463
-
16,745
16,745
35,208
659,393
694,601

Page 18

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The Office of Health Economics ("the company") meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Statement of Financial Activities (SOFA) and Balance Sheet consolidate the financial statements of the company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Financial Activities in these financial statements.

The net income and expenditure for the period dealt with in the accounts of the parent company, after receipt of gift aid, was a net income of £456,571 (2024 - £474,894) .

In considering whether it continues to be appropriate to prepare financial statements on a going concern basis the Trustees have considered the ongoing support from the ABPI, the evaluation of the conflicts around the world, inflation and interest rate rises, and concludes that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements. The ABPI has confrmed its support and provided a letter confirming this.

There is no indication that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. We have come to this conclusion following a review of the liabilities and cash flow over the next 12-18 months from the date of approval of the accounts.

1.2 Company Status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 5. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.3 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Page 19

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies (continued)

1.4 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Consultancy and research project income is included to the extent that it has been earned in the period by reference to appropriate project milestones or project completion. Payments received in advance for consultancy projects are included in Creditors (Deferred Income) to the extent that these have not been earned in the period. Project income yet to be invoiced has been accrued within Debtors (Accrued Income).

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's educational operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

1.6 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Page 20

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies (continued)

1.6 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

IT Software

33% straight line

1.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.8 Cash and Cash Equivalents

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.9 Liabilities

Liabilities and provisions are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.10 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments.

Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Page 21

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies (continued)

1.11 Foreign currencies

The company's and group's functional and presentational currency is Pounds Sterling.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Consolidated Statement of Financial Activities incorporating the income and expenditure account.

1.12 Pensions

Another group entity operates a defined contribution pension scheme and the pension charge represents the amounts which have been recharged by another group entity in respect of the staff pensions payable to the funds in respect of the year.

2. Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgement:

(a) Impairment of trade and other debtors

The company makes a judgement of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the credit rating of the debtor, ageing profile of the debtors and historical experience. See Note 10 for the net carrying amount of debtors.

(b) Accrued and deferred income

The group reviews the amount of any income generated but not invoiced to customers at the year end, or vice versa, based on the extent of services provided and what is expected to be invoiced after the period end, or already been invoiced before the period end.

Page 22

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

3. Analysis of expenditure by activities

Unrestricted
Direct charitable expenditure
Support costs - governance
Support costs - general
Total 2025
Unrestricted
Direct charitable expenditure
Support costs - governance
Support costs - general
Total 2024
Activities
undertaken
directly
2025
£
1,803,241
-
-
1,803,241
Activities
undertaken
directly
2024
£
1,989,101
-
-
1,989,101
Support
costs
2025
£
-
32,088
83,367
115,455
Support
costs
2024
£
-
114,027
94,323
208,350
Total
funds
2025
£
1,803,241
32,088
83,367
1,918,696
Total
funds
2024
£
1,989,101
114,027
94,323
2,197,451

Included within Direct charitable expenditure are staff costs totalling £1,017,941 ( 2024 - £1,225,077 ). A further £2,547,864 ( 2024 - £2,145,635 ) of staff costs are included within OHE Consulting Limited trading activities within Note 4. An analysis of total staff costs of £3,565,805 ( 2024 - £3,370,712 ), is provided in Note 6.

Page 23

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

3. Analysis of expenditure by activities (continued)

Analysis of support costs

Legal and professional related costs
Accountancy related costs
Human resources related costs
Facilities related costs
IT related costs
Other office support related costs
Total 2025
Legal and professional related costs
Accountancy related costs
Human resources related costs
Facilities related costs
IT related costs
Other office support related costs
Total 2024
Governance
2025
£
6,329
25,759
-
-
-
-
32,088
Governance
2024
£
84,554
29,473
-
-
-
-
114,027
General
2025
£
-
-
28,025
1,260
19,473
34,609
83,367
General
2024
£
-
-
26,582
3,767
21,035
42,939
94,323
Total
funds
2025
£
6,329
25,759
28,025
1,260
19,473
34,609
115,455
Total
funds
2024
£
84,554
29,473
26,582
3,767
21,035
42,939
208,350

Page 24

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

4. Analysis of expenditure by expenditure type

5. Other costs
2025
Other costs
2024
OHE Consulting trading activities £
3,312,806
£
2,609,887
Direct charitable expenditure 1,803,241 1,989,101
General support costs 83,367 94,323
Charitable activities 1,886,608 2,083,424
Expenditure on governance 32,088 114,027
1,918,696 2,197,451
Total Expenditure 5,231,502 4,807,338
Auditor's remuneration
Fees payable to the company's auditor and its associates in respect of:
Audit-related assurance services
2025
£
10,000
2024
£
10,000

6. Staff costs

Staff costs, including key management personnel (see Note 7), were as follows:

Wages and salaries
Social security costs
Contributions to defined contribution pension
schemes (Note 16)
Group
2025
£
2,982,021
390,956
192,828
3,565,805
Group
2024
£
2,845,429
332,758
192,525
3,370,712
Company
2025
£
847,191
112,851
57,899
1,017,941
Company
2024
£
1,034,880
129,120
61,077
1,225,077

Page 25

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

6. Staff costs (continued)

The average number of persons employed by the company during the year was as follows:

Key management personnel
Administrative staff
Group
2025
No.
3
35
38
Group
2024
No.
3
33
36
Company
2025
No.
3
35
38
Company
2024
No.
3
33
36

The number of higher paid employees was:

Group Group
2025 2024
No. No.
£60,001 - £70,000 3 2
£70,001 - £80,000 2 3
£80,001 - £90,000 3 4
£90,001 - £100,000 2 3
£100,001 - £110,000 1 1
£110,001 - £120,000 2 1
£120,001 - £130,000 - 1
£130,001 - £140,000 1 -
£140,001 - £150,000 - 1
£160,001 - £170,000 1 1
£240,001 - £250,000 1 1
£350,001 - £360,000 - 1
£380,001 - £390,000 1 -

The total cost that is reflected in the above bandings is made up of wages and salaries, social security costs and defined contribution pension scheme contributions.

Page 26

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

7. Key management personnel

Wages and salaries
Social security costs
Cost of defined contribution scheme (Note 16)
2025
£
797,971
119,696
28,303
945,970
2024
£
771,027
106,402
19,721
897,150

In addition to the Board of Trustees, there were 3 ( 2024 - 3 ) key management personnel, 2 ( 2024 - 2 ) of which accrued benefits under another group entity's defined contribution pension scheme during the period.

8. Trustees' fees

Fees for services provided (see below)
Reimbursed travel expenses paid to 1 trustee
2025
£
21,398
-
21,398
2024
£
26,470
269
26,739

The highest paid Trustee received remuneration of £NIL ( 2024 - £NIL ).

A Charlesworth, Trustee, received fees for services provided during the period of £14,398 ( 2024 - £13,606 ).

R Tarricone, Trustee, received fees for services provided during the period of £7,000 (2024 - £NIL) .

M Kyle, Trustee, received fees for services provided during the period of £NIL (2024 - £12,864) .

The fees paid to the two Trustees noted above during the period related to the provision of consultancy and advisory services in respect of direct charitable activities. This directly contributed to the company achieving its' objectives.

The services provided by the Trustees relates to advice in respect of specialist areas within health economics and healthcare policy and hence it would have proven difficult to obtain these services from a third party.

No Trustees received fees for being Trustees and no other remuneration or expenses were paid to the Trustees during the period.

The above payments were made in line with the authority contained within the Charity's memorandum and articles of association.

Page 27

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

9. Tangible fixed assets

Group and Company

Cost or valuation
At 1 January 2025
At 31 December 2025
Depreciation
At 1 January 2025
Charge for the year
At 31 December 2025
Net book value
At 31 December 2025
At 31 December 2024
IT software
£
47,685
47,685
30,465
15,895
46,360
1,325
17,220

10. Debtors

Due within one year
Trade debtors
Amounts owed by group undertakings
Other debtors
Prepayments and accrued income
Group
2025
£
1,456,008
-
7,238
895,252
2,358,498
Group
2024
£
2,010,319
-
54,249
660,352
2,724,920
Company
2025
£
164,753
2,415,112
7,238
455,631
3,042,734
Company
2024
£
185,788
1,597,341
54,249
230,497
2,067,875

Page 28

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

11. Creditors: Amounts falling due within one year

Trade creditors
Amounts owed to ultimate parent
Other taxation and social security
Other creditors
Accruals and deferred income
Deferred income at the beginning of the year
Resources deferred during the year
Amounts released from previous periods
Deferred income at the end of the year
Financial instruments
Financial assets
Financial assets measured at fair value
through income and expenditure
Financial assets measured at amortised cost
Financial liabilities
Financial liabilities measured at cost less
impairment
Group
2025
£
44,024
1,684,993
4,346
3,047
1,742,249
3,478,659
Group
2025
£
880,844
1,389,267
(880,844)
1,389,267
Group
2025
£
3,344,965
2,329,146
5,674,111
Group
2025
£
2,291,392
Group
2024
£
61,287
578,890
4,678
43,000
1,181,328
1,869,183
Group
2024
£
581,655
880,844
(581,655)
880,844
Group
2024
£
694,601
2,012,754
2,707,355
Group
2024
£
988,339
Company
2025
£
27,432
1,623,249
4,346
3,047
484,468
2,142,542
Company
2025
£
111,904
337,687
(111,904)
337,687
Company
2025
£
1,122,611
3,013,381
4,135,992
Company
2025
£
1,804,854
Company
2024
£
47,657
517,369
4,678
2,310
251,015
823,029
Company
2024
£
57,369
111,904
(57,369)
111,904
Company
2024
£
305,491
1,785,564
2,091,055
Company
2024
£
711,125

12. Financial instruments

Page 29

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

12. Financial instruments (continued)

Financial assets measured at fair value through income and expenditure comprise of cash and cash equivalents.

Financial assets measured at amortised cost compromise of debtors falling due within one year, excluding prepayments.

Financial liabilities measured at cost less impairment comprise of creditors falling due within one year, excluding deferred income.

13. Provisions

Group

Additions Provisions
£
202,000
202,000

Included within the provisions balance at the year end is an amount for ongoing legal related matters.

14. Reconciliation of net movement in funds to net cash flow provided by operating activities

Net surplus for the year (as per Statement of Financial Activities)
Adjustments for:
Depreciation charges
Decrease/(Increase) in debtors
Increase in creditors
Interest received
Net cash provided by operating activities
Group
2025
£
456,571
15,895
366,422
1,811,476
(22,849)
2,627,515
Group
2024
£
474,894
15,895
(845,541)
389,960
(16,745)
18,463

Page 30

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

15. Cash and cash equivalents

Cash at bank and in hand
Total cash and cash equivalents
Group
2025
£
3,344,965
3,344,965
Group
2024
£
694,601
694,601

16. Analysis of changes in net debt (Group)

Cash at bank and in hand At 1
January
2025
£
694,601
694,601
Cash flows
£
2,650,364
2,650,364
At 31
December
2025
£
3,344,965
3,344,965

17. Pension commitments

The ultimate parent entity operates a defined benefit contribution pension scheme. The pensions cost charge represents contributions which were payable to the fund, and were recharged by another group entity for staff undertaking work on behalf of the OHE Group, and amounted to £192,828 (2024 - £192,525) for the group and £57,899 ( 2024 - £61,077 ) for the company.

18. Related party transactions

During the period two Trustees received fees for services totalling £21,398 ( 2024 - £26,470 ) (refer to Note 8 for details). At the balance sheet date, no amount ( 2024 - £Nil ) of this was outstanding.

During the period the company received research grants totalling £100,000 ( 2024 - £150,000 ) from the ABPI.

During the period, the group and company incurred support costs totalling £395,592 and £115,456 respectively ( 2024 - £443,280 and £208,350 ), which were recharged by the ABPI (refer to Note 19 below).

During the current and comparative period, the company received a transfer of profits from OHE Consulting Limited, which were transferred as a qualifying charitable donation via Gift Aid (refer to Note 20 below).

Page 31

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

19. Ultimate parent undertaking and controlling party

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry Limited ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. The Association represents innovative research based biopharmaceutical companies, large, medium and small, leading an exciting era of bioscience in the UK. This company prepares consolidated financial statements. These are available to the public and may be obtained from 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB.

20. Principal subsidiaries

The following was a subsidiary undertaking of the company:

Name Country of Incorporation Principal activity Holding
OHE Consulting Limited United Kingdom Provision of policy and 100%
strategic expertise on
healthcare and related
matters.

During the period, OHE Consulting Limited, registered company number 09853113, generated income totalling £4,414,549 ( 2024 - £4,204,016 ), and incurred expenditure totalling £3,312,806 ( 2024 - £2,602,333 ), plus interest received of £17,729 (2024 - £13,255 ), generating profits for the period of £1,119,472 ( 2024 - £1,614,938 ). OHE Consulting Limited elected to transfer its profits to the company by way of a qualifying charitable donation via Gift Aid, leaving aggregated assets in OHE Consulting Limited of £1 at the period end.

21. Post balance sheet events

There have been no significant events affecting the group since the year-end.

Page 32

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

Registered number: 09848965 Charity number: 1170829

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2025

Trustees Ms A R Charlesworth, Trustee
Dr R D Torbett, Trustee
Mr W P Holmes, Trustee
Mr W B F Brouwer, Trustee
Mr P Catchpole, Trustee (resigned 13 November 2025)
Mr T E Allvin, Trustee
Ms R Tarricone, Trustee (appointed 20 May 2025)
Ms V Jordan, Trustee (appointed 1 December 2025)
Company registered
number
09848965
Charity registered
number
1170829
Registered office
2nd Floor Goldings House
Hay's Galleria
2 Hay's Lane
London
SE1 2HB
Company secretary
R Hollingsworth
Chief executive officer
Prof G Cookson
Independent auditor
BDO LLP
55 Baker Street
London
United Kingdom
W1U 7EU
Bankers
National Westminster Bank Plc
PO Box 414
38 Strand
London
WC2H 5JB

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

CONTENTS
Page
Trustees' Report 1 - 7
Independent Auditor's Report 8 - 13
Consolidated Statement of Financial Activities 14
Consolidated Balance Sheet 15
Company Balance Sheet 16 - 17
Consolidated Statement of Cash Flows 18
Notes to the Financial Statements 19 - 32

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

The Trustees, who are also directors for the purposes of company law, present their report together with the audited consolidated financial statements of the group and the company, ‘The Office of Health Economics’ ("OHE", "the charitable company", "the charity" or "the company") (charity number 1170829) (registered in England and Wales), and its subsidiary undertaking OHE Consulting Limited (registered in England and Wales) (collectively "the group") for year ended 31 December 2025.

The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019.

As stated in Note 19 to the financial statements the ultimate parent company of OHE is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"). The registered address of the ABPI is 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB. The ABPI provides a research grant to OHE to enable it to independently progress its charitable purpose and objectives as summarised below.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued in October 2019 ("Charities SORP FRS 102").

Objectives and activities

The Office of Health Economics’ objectives are to advance the education of the public in general/health care payers/policy makers, particularly patients and healthcare professionals, on the subject of health economics and healthcare policy.

Activities in furtherance of this include, in particular, but not exclusively:

The term "health economics" means the application of economic theory, models and empirical techniques to the analysis of decisions making by people, health care providers and governments with respect to health and health care.

In planning the activities of the charity, the Trustees have had regard to the Charity Commission's guidance on public benefit. They consider the information which follows in this annual report, about the company's aims, activities and achievements in the areas of interest that the company supports demonstrates the benefit to its beneficiaries and through them to the public.

Page 1

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Achievements and performance

OHE has once again undertaken an ambitious programme of original research, generating findings published in high quality peer reviewed journals, and via its own publication series, on the economics of health technology appraisal, the economics of health care systems and the economics of the life sciences industry. OHE’s work has direct relevance to policy, and evidence from our research programme informs health care decision making and health care policy. OHE also contributes directly to the development and promotion of excellence in the field of health economics via our seminars, lectures, leadership roles in professional societies, and other academic activities. OHE’s consulting arm has produced authoritative analyses for our clients and a financial surplus from which it contributes to the financial sustainability of OHE as a research charity.

The company and group have continued to perform successfully this year. Internal and external funding has continued to be provided to finance a wide range of research projects and consultancy advice provided to the life sciences industry, public sector organisations and the ABPI.

The key performance indicators are external research funding targets, consultancy income targets and operating expenditure targets. In 2025, research funding was 105% of target and consultancy income was 115% of target.Consultancy income grew 5% compared to the previous year whilst research funding grew 18%. Operating expenditure in 2025 was 103% of the budget target. Overall, the company made a net operating loss, before receipt of Gift Aid from OHE Consulting Limited, as it made significant investments in charitable work. However, overall the group reported a strong surplus of more than 340% of target which has enabled it to reach its reserves target.

Financial review

a. Going concern

After making appropriate enquiries, and getting confirmation of on going support from ABPI (Note 18), the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

The Trustees are aware that the operational and financial implications of the various conflict in the world, have been considered by the Governance Committee of OHE’s ultimate parent company the ABPI. The Governance Committee have concluded that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements.

Page 2

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Financial review (continued)

b. Reserves policy

The Trustees have examined the charitable company's requirement for resources in light of the main risks to the company and have no outstanding commitments or cash demand which are not adequately covered by existing resources.

The group’s reserves policy continues to ensure that the company has adequate cash and reserves to meet current and future needs, and this is reviewed annually as part of the budget process. The charity reserves were £2,024,129 (2024 - £1,567,558 ) as at the year ended 31 December 2025.

The group's reserves target is 6 months of payroll expenditure. For 2026, that would be a target of £1,994,802 which has now been met. The Trustees and Executive Management will review the Reserves Policy this year whilst continuing to target a 5% surplus. We suggest that generating a surplus which is too significant would not be in accordance with delivering on our Charitable Objects.

The policy will seek to balance the goal of sustainability with the needs to be efficient as a not-for-profit organisation. Research funding and consultancy contracts are always agreed before making any expenditure commitments.

c. Work programmes and funding

The company's current work programme is supported by research grants and consultancy revenues from a wide range of UK and international sources including the ABPI and other commercial clients, as well as government agencies, European Commission, and a number of charitable and other organisations.

d. Results for the year

OHE Consulting Limited, the company's wholly owned subsidiary, made an operating profit of £1,119,472 (2024 - £1,614,938) and made a qualifying charitable donation via Gift Aid for this amount to its parent company, the OHE.

The company made an operating loss of £662,901 (2024 - £1,194,790) prior to the Gift Aid payment received from OHE Consulting Limited, and therefore overall the group realised a profit for 2025 of £456,571 (2024 - profit of £474,894) .

e. Fundraising

Section 162a of the Charities Act 2011 requires charities to make a statement regarding fundraising activities. Although we do not undertake fundraising from the general public, the legislation defines fundraising as "soliciting or otherwise procuring money or other property for charitable purposes." Such amounts receivable would be presented in our accounts as "voluntary income" and includes legacies and grants.

Page 3

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Structure, governance and management

a. Constitution and legal structure

The company is registered as a charitable company limited by guarantee (charity number 1170829) and was set up by a Memorandum of Association on 29 October 2015.

The company has a wholly owned subsidiary, OHE Consulting Limited, a company limited by shares. This company provides health economic consultancy services to the life sciences industry. The legal structure enables the research activities of the charitable company to be kept separate to the commercial consultancy activity. Both companies share the same directors and key management personnel.

b. Methods of appointment or election of Trustees

The management of the company is the responsibility of the Trustees who are elected and co opted under the terms of the Memorandum of Association.

The ABPI, as the sole member of the charity, has the sole right to appoint Trustees to the Board of the charity.

c. Policies adopted for the induction and training of Trustees

As part of their training, Trustees are provided a comprehensive 'operating' manual, which includes the charitable company's Memorandum of Association and Charity Commission guidance on trustee responsibility. All Trustees are aware of their legal duties and obligations in respect of the management of the charitable company, including in relation to the protection of its assets.

d. Pay policy for key management personnel

Two Trustees (2024: Two) received fees for services during the period. Details of Trustees' fees, expenses and related party transactions are disclosed in Note 8 to the financial statements.

The company uses benchmark data from other research and consultancy organisations to help set pay and remuneration for key staff. Annual pay reviews are then linked to performance against agreed objectives, inflation rates and market trends.

Page 4

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Structure, governance and management (continued)

e. Organisational structure and decision-making policies

The company is governed by the Board of Trustees. The Trustees of the company during the period were as follows:

Ms A Charlesworth, Trustee Mr R D Torbett, Trustee Mr W P Holmes, Trustee Mr W B F Brouwer, Trustee Mr P Catchpole, Trustee (resigned 13 November 2025) Mr T E Allvin, Trustee Ms R Tarricone, Trustee (appointed 20 May 2025) Ms V Jordan, Trustee (appointed 1 December 2025)

In addition to the Board of Trustees, the company is managed by the Executive Management Team, and advised by an Editorial Committee, a Research Committee and a Policy Committee. Each Committee is Chaired by a Trustee and provides regular reports to the entire Board.

The Executive Management Team during the period were as follows:

Prof G Cookson (Chief Executive) Prof L Steuten (Deputy Chief Executive) Prof M Jofre Bonet (Chief Research Officer and Head of Education)

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. Transactions with other related parties are disclosed in Note 18.

As per the company Articles, the ABPI is entitled to appoint a majority of the Trustees (4/7), one of which is the Chief Executive of the ABPI.

f. Risk management

The Trustees have assessed the major risks to which the company is exposed, in particular those related to the operations and finances of the company, and are satisfied that systems and procedures are in place to manage the exposure to the major risks. They have also considered the reputational risk of the company and ensure transparency and strong communiaction is carried out with stakeholders.

The principal risks facing the company and group are a reduction in research funding or consultancy income together with the loss of key staff. Funding and income wins and proposals are closely monitored against budget expectations by the Executive Management Team and if necessary cost savings are identified to cover any income shortfall. A competitive remuneration package, development through work experience and succession planning are used to attract and retain high calibre staff.

Page 5

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Plans for future periods

OHE will continue to develop its programme of original research, supported by a wide range of research funders in the UK and internationally. OHE will continue to expand the focus of our work beyond the UK, and to focus effort on maximising the impact of our research on improving health care decision making both in the UK and further afield. In its role as an established charity, OHE will be developing evidence based policy positions, which it will disseminate by engaging with a wide range of stakeholders via events, media commentaries, and publications.

Statement of Trustees' responsibilities

The Trustees (who are also directors of OHE for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial period. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and group for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Group and the company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditor

Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that:

Page 6

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025

Auditor

The auditors, BDO LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127). The registered office is 55 Baker Street, London, W1U 7EU.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2016 relating to small companies.

This report was approved by the Trustees, and signed on their behalf by:

Trustee

Trustee

Date: 29-Sep-2026 | 14:07 BST Date: 29-Sep-2026 | 13:23 BST

Page 7

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS

Opinion

In our opinion the financial statements:

We have audited the financial statements of the Office of Health Economics (“the Parent Charitable Company”) and its subsidiaries (“the Group”) for the year ended 31 December 2025 which comprise the following:

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remain independent of the Group and the Parent Charitable Company in accordance with the ethical requirements relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Page 8

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group and the Parent Charitable Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Group and the Parent Charitable Company’s ability to continue as a going concern.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Report and Financial Statements, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Page 9

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Other Companies Act 2006 reporting

In our opinion, based on the work undertaken in the course of the audit:

In the light of the knowledge and understanding of the Group and the Parent Charitable Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion;

Responsibilities of Trustees

As explained more fully in the Statement of Trustees’ responsibilities, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group’s and the Parent Charitable Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations, or have no realistic alternative but to do so.

Page 10

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the Charitable Company and management.

Extent to which the audit was capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Non-compliance with laws and regulations

Based on:

we considered the significant laws and regulations to be the applicable accounting framework (UK GAAP), Companies Act 2006, Charities Act 2011, and relevant UK tax legislation.

The Group is also subject to laws and regulations where the consequence of non-compliance could have a material effect on the amount or disclosures in the financial statements, for example through the imposition of fines or litigations. We identified such laws and regulations to be employment law, data protection and health and safety legislation.

Our procedures in respect of the above included:

Page 11

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Fraud

We assessed the susceptibility of the financial statements to material misstatement, including fraud. Our risk assessment procedures included:

Based on our risk assessment, we considered the areas most susceptible to fraud to be management override of controls through the posting of inappropriate journal entries and early consultancy and research revenue recognition.

Our procedures in respect of the above included:

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members who were all deemed to have appropriate competence and capabilities and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

Our audit procedures were designed to respond to risks of material misstatement in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery, misrepresentations or through collusion. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

A further description of our responsibilities for the audit of the financial statements is located at the Financial Reporting Council’s (“FRC’s”) website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Page 12

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE OFFICE OF HEALTH ECONOMICS (CONTINUED)

Use of our report

This report is made solely to the Charitable Company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Charitable Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Charitable Company and the Charitable Company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Fiona Condron (Statutory Auditor)

For and on behalf of BDO LLP, Statutory Auditor London, UK

Date: 29 September 2026

BDO LLP is a limited liability partnership registered in England and Wales (with registered number OC305127).

Page 13

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025

Note
Income from:
Donations and research grant
Charitable activities
Other trading activities
Interest receivable
Total income
Expenditure on:
Costs of other trading activities
4
Charitable activities
4
Total expenditure
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward
Unrestricted
funds
2025
£
302,317
948,358
4,414,549
22,849
5,688,073
3,312,806
1,918,696
5,231,502
456,571
1,567,558
456,571
2,024,129
Total
funds
2025
£
302,317
948,358
4,414,549
22,849
5,688,073
3,312,806
1,918,696
5,231,502
456,571
1,567,558
456,571
2,024,129
Total
funds
2024
£
205,484
855,987
4,204,016
16,745
5,282,232
2,609,887
2,197,451
4,807,338
474,894
1,092,664
474,894
1,567,558

The Consolidated Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 19 to 32 form part of these financial statements.

Page 14

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2025

Note
Fixed assets
Tangible assets
9
Current assets
Debtors
10
Cash at bank and in hand
Creditors: amounts falling due within one
year
11
Net current assets
Total assets less current liabilities
Provisions for liabilities
Net assets
Total net assets
Charity funds
Restricted funds
Unrestricted funds
Total funds
2,358,498
3,344,965
5,703,463
(3,478,659)
2025
£
1,325
1,325
2,224,804
2,226,129
(202,000)
2,024,129
2,024,129
-
2,024,129
2,024,129
2,724,920
694,601
3,419,521
(1,869,183)
2024
£
17,220
17,220
1,550,338
1,567,558
-
1,567,558
1,567,558
-
1,567,558
1,567,558

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Trustee Trustee

Date: 29-Sep-2026 | 14:07 BST

Date: 29-Sep-2026 | 13:23 BST

The notes on pages 19 to 32 form part of these financial statements.

Page 15

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET AS AT 31 DECEMBER 2025

Note
Fixed assets
Tangible assets
9
Investments
Current assets
Debtors
10
Cash at bank and in hand
Creditors: amounts falling due within one
year
11
Net current assets
Total net assets less current liabilities
Charity funds
Unrestricted funds
Total funds
3,042,734
1,122,611
4,165,345
(2,142,542)
2025
£
1,325
1
1,326
2,022,803
2,024,129
2,024,129
2,024,129
2,067,875
305,491
2,373,366
(823,029)
2024
£
17,220
1
17,221
1,550,337
1,567,558
1,567,558
1,567,558

Page 16

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee) REGISTERED NUMBER: 09848965

COMPANY BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2025

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements.

The profit after tax after gift aid of the parent Company for the year was £456,571 (2024 - £474,894) .

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Trustee Trustee

Date: 29-Sep-2026 | 14:07 BST Date: 29-Sep-2026 | 13:23 BST

The notes on pages 19 to 32 form part of these financial statements.

Page 17

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025

Cash flows from operating activities
Net cash generated from operating activities (note 14)
Cash flows from investing activities
Net cash provided by investing activities
Cash flows from financing activities
Interest received
Net cash provided by financing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
The notes on pages 19 to 32 form part of these financial statements
2025
£
2,627,515
-
22,849
22,849
2,650,364
694,601
3,344,965
2024
£
18,463
-
16,745
16,745
35,208
659,393
694,601

Page 18

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS

(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The Office of Health Economics ("the company") meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The Statement of Financial Activities (SOFA) and Balance Sheet consolidate the financial statements of the company and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis.

The company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Financial Activities in these financial statements.

The net income and expenditure for the period dealt with in the accounts of the parent company, after receipt of gift aid, was a net income of £456,571 (2024 - £474,894) .

In considering whether it continues to be appropriate to prepare financial statements on a going concern basis the Trustees have considered the ongoing support from the ABPI, the evaluation of the conflicts around the world, inflation and interest rate rises, and concludes that the ABPI has sufficient financial reserves, income and expenditure controls to avoid any liquidity issues for at least 12 months from the approval of these financial statements. The ABPI has confrmed its support and provided a letter confirming this.

There is no indication that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. We have come to this conclusion following a review of the liabilities and cash flow over the next 12-18 months from the date of approval of the accounts.

1.2 Company Status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 5. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.3 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes.

Page 19

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies (continued)

1.4 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Consultancy and research project income is included to the extent that it has been earned in the period by reference to appropriate project milestones or project completion. Payments received in advance for consultancy projects are included in Creditors (Deferred Income) to the extent that these have not been earned in the period. Project income yet to be invoiced has been accrued within Debtors (Accrued Income).

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Group's objectives, as well as any associated support costs.

Support costs are those costs incurred directly in support of expenditure on the objects of the company and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's educational operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

1.6 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Page 20

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies (continued)

1.6 Tangible fixed assets and depreciation (continued)

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

IT Software

33% straight line

1.7 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.8 Cash and Cash Equivalents

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.9 Liabilities

Liabilities and provisions are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.10 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments.

Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Page 21

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. Accounting policies (continued)

1.11 Foreign currencies

The company's and group's functional and presentational currency is Pounds Sterling.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the reporting date.

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.

Exchange gains and losses are recognised in the Consolidated Statement of Financial Activities incorporating the income and expenditure account.

1.12 Pensions

Another group entity operates a defined contribution pension scheme and the pension charge represents the amounts which have been recharged by another group entity in respect of the staff pensions payable to the funds in respect of the year.

2. Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgement:

(a) Impairment of trade and other debtors

The company makes a judgement of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the credit rating of the debtor, ageing profile of the debtors and historical experience. See Note 10 for the net carrying amount of debtors.

(b) Accrued and deferred income

The group reviews the amount of any income generated but not invoiced to customers at the year end, or vice versa, based on the extent of services provided and what is expected to be invoiced after the period end, or already been invoiced before the period end.

Page 22

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

3. Analysis of expenditure by activities

Unrestricted
Direct charitable expenditure
Support costs - governance
Support costs - general
Total 2025
Unrestricted
Direct charitable expenditure
Support costs - governance
Support costs - general
Total 2024
Activities
undertaken
directly
2025
£
1,803,241
-
-
1,803,241
Activities
undertaken
directly
2024
£
1,989,101
-
-
1,989,101
Support
costs
2025
£
-
32,088
83,367
115,455
Support
costs
2024
£
-
114,027
94,323
208,350
Total
funds
2025
£
1,803,241
32,088
83,367
1,918,696
Total
funds
2024
£
1,989,101
114,027
94,323
2,197,451

Included within Direct charitable expenditure are staff costs totalling £1,017,941 ( 2024 - £1,225,077 ). A further £2,547,864 ( 2024 - £2,145,635 ) of staff costs are included within OHE Consulting Limited trading activities within Note 4. An analysis of total staff costs of £3,565,805 ( 2024 - £3,370,712 ), is provided in Note 6.

Page 23

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

3. Analysis of expenditure by activities (continued)

Analysis of support costs

Legal and professional related costs
Accountancy related costs
Human resources related costs
Facilities related costs
IT related costs
Other office support related costs
Total 2025
Legal and professional related costs
Accountancy related costs
Human resources related costs
Facilities related costs
IT related costs
Other office support related costs
Total 2024
Governance
2025
£
6,329
25,759
-
-
-
-
32,088
Governance
2024
£
84,554
29,473
-
-
-
-
114,027
General
2025
£
-
-
28,025
1,260
19,473
34,609
83,367
General
2024
£
-
-
26,582
3,767
21,035
42,939
94,323
Total
funds
2025
£
6,329
25,759
28,025
1,260
19,473
34,609
115,455
Total
funds
2024
£
84,554
29,473
26,582
3,767
21,035
42,939
208,350

Page 24

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

4. Analysis of expenditure by expenditure type

5. Other costs
2025
Other costs
2024
OHE Consulting trading activities £
3,312,806
£
2,609,887
Direct charitable expenditure 1,803,241 1,989,101
General support costs 83,367 94,323
Charitable activities 1,886,608 2,083,424
Expenditure on governance 32,088 114,027
1,918,696 2,197,451
Total Expenditure 5,231,502 4,807,338
Auditor's remuneration
Fees payable to the company's auditor and its associates in respect of:
Audit-related assurance services
2025
£
10,000
2024
£
10,000

6. Staff costs

Staff costs, including key management personnel (see Note 7), were as follows:

Wages and salaries
Social security costs
Contributions to defined contribution pension
schemes (Note 16)
Group
2025
£
2,982,021
390,956
192,828
3,565,805
Group
2024
£
2,845,429
332,758
192,525
3,370,712
Company
2025
£
847,191
112,851
57,899
1,017,941
Company
2024
£
1,034,880
129,120
61,077
1,225,077

Page 25

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

6. Staff costs (continued)

The average number of persons employed by the company during the year was as follows:

Key management personnel
Administrative staff
Group
2025
No.
3
35
38
Group
2024
No.
3
33
36
Company
2025
No.
3
35
38
Company
2024
No.
3
33
36

The number of higher paid employees was:

Group Group
2025 2024
No. No.
£60,001 - £70,000 3 2
£70,001 - £80,000 2 3
£80,001 - £90,000 3 4
£90,001 - £100,000 2 3
£100,001 - £110,000 1 1
£110,001 - £120,000 2 1
£120,001 - £130,000 - 1
£130,001 - £140,000 1 -
£140,001 - £150,000 - 1
£160,001 - £170,000 1 1
£240,001 - £250,000 1 1
£350,001 - £360,000 - 1
£380,001 - £390,000 1 -

The total cost that is reflected in the above bandings is made up of wages and salaries, social security costs and defined contribution pension scheme contributions.

Page 26

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

7. Key management personnel

Wages and salaries
Social security costs
Cost of defined contribution scheme (Note 16)
2025
£
797,971
119,696
28,303
945,970
2024
£
771,027
106,402
19,721
897,150

In addition to the Board of Trustees, there were 3 ( 2024 - 3 ) key management personnel, 2 ( 2024 - 2 ) of which accrued benefits under another group entity's defined contribution pension scheme during the period.

8. Trustees' fees

Fees for services provided (see below)
Reimbursed travel expenses paid to 1 trustee
2025
£
21,398
-
21,398
2024
£
26,470
269
26,739

The highest paid Trustee received remuneration of £NIL ( 2024 - £NIL ).

A Charlesworth, Trustee, received fees for services provided during the period of £14,398 ( 2024 - £13,606 ).

R Tarricone, Trustee, received fees for services provided during the period of £7,000 (2024 - £NIL) .

M Kyle, Trustee, received fees for services provided during the period of £NIL (2024 - £12,864) .

The fees paid to the two Trustees noted above during the period related to the provision of consultancy and advisory services in respect of direct charitable activities. This directly contributed to the company achieving its' objectives.

The services provided by the Trustees relates to advice in respect of specialist areas within health economics and healthcare policy and hence it would have proven difficult to obtain these services from a third party.

No Trustees received fees for being Trustees and no other remuneration or expenses were paid to the Trustees during the period.

The above payments were made in line with the authority contained within the Charity's memorandum and articles of association.

Page 27

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

9. Tangible fixed assets

Group and Company

Cost or valuation
At 1 January 2025
At 31 December 2025
Depreciation
At 1 January 2025
Charge for the year
At 31 December 2025
Net book value
At 31 December 2025
At 31 December 2024
IT software
£
47,685
47,685
30,465
15,895
46,360
1,325
17,220

10. Debtors

Due within one year
Trade debtors
Amounts owed by group undertakings
Other debtors
Prepayments and accrued income
Group
2025
£
1,456,008
-
7,238
895,252
2,358,498
Group
2024
£
2,010,319
-
54,249
660,352
2,724,920
Company
2025
£
164,753
2,415,112
7,238
455,631
3,042,734
Company
2024
£
185,788
1,597,341
54,249
230,497
2,067,875

Page 28

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

11. Creditors: Amounts falling due within one year

Trade creditors
Amounts owed to ultimate parent
Other taxation and social security
Other creditors
Accruals and deferred income
Deferred income at the beginning of the year
Resources deferred during the year
Amounts released from previous periods
Deferred income at the end of the year
Financial instruments
Financial assets
Financial assets measured at fair value
through income and expenditure
Financial assets measured at amortised cost
Financial liabilities
Financial liabilities measured at cost less
impairment
Group
2025
£
44,024
1,684,993
4,346
3,047
1,742,249
3,478,659
Group
2025
£
880,844
1,389,267
(880,844)
1,389,267
Group
2025
£
3,344,965
2,329,146
5,674,111
Group
2025
£
2,291,392
Group
2024
£
61,287
578,890
4,678
43,000
1,181,328
1,869,183
Group
2024
£
581,655
880,844
(581,655)
880,844
Group
2024
£
694,601
2,012,754
2,707,355
Group
2024
£
988,339
Company
2025
£
27,432
1,623,249
4,346
3,047
484,468
2,142,542
Company
2025
£
111,904
337,687
(111,904)
337,687
Company
2025
£
1,122,611
3,013,381
4,135,992
Company
2025
£
1,804,854
Company
2024
£
47,657
517,369
4,678
2,310
251,015
823,029
Company
2024
£
57,369
111,904
(57,369)
111,904
Company
2024
£
305,491
1,785,564
2,091,055
Company
2024
£
711,125

12. Financial instruments

Page 29

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

12. Financial instruments (continued)

Financial assets measured at fair value through income and expenditure comprise of cash and cash equivalents.

Financial assets measured at amortised cost compromise of debtors falling due within one year, excluding prepayments.

Financial liabilities measured at cost less impairment comprise of creditors falling due within one year, excluding deferred income.

13. Provisions

Group

Additions Provisions
£
202,000
202,000

Included within the provisions balance at the year end is an amount for ongoing legal related matters.

14. Reconciliation of net movement in funds to net cash flow provided by operating activities

Net surplus for the year (as per Statement of Financial Activities)
Adjustments for:
Depreciation charges
Decrease/(Increase) in debtors
Increase in creditors
Interest received
Net cash provided by operating activities
Group
2025
£
456,571
15,895
366,422
1,811,476
(22,849)
2,627,515
Group
2024
£
474,894
15,895
(845,541)
389,960
(16,745)
18,463

Page 30

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

15. Cash and cash equivalents

Cash at bank and in hand
Total cash and cash equivalents
Group
2025
£
3,344,965
3,344,965
Group
2024
£
694,601
694,601

16. Analysis of changes in net debt (Group)

Cash at bank and in hand At 1
January
2025
£
694,601
694,601
Cash flows
£
2,650,364
2,650,364
At 31
December
2025
£
3,344,965
3,344,965

17. Pension commitments

The ultimate parent entity operates a defined benefit contribution pension scheme. The pensions cost charge represents contributions which were payable to the fund, and were recharged by another group entity for staff undertaking work on behalf of the OHE Group, and amounted to £192,828 (2024 - £192,525) for the group and £57,899 ( 2024 - £61,077 ) for the company.

18. Related party transactions

During the period two Trustees received fees for services totalling £21,398 ( 2024 - £26,470 ) (refer to Note 8 for details). At the balance sheet date, no amount ( 2024 - £Nil ) of this was outstanding.

During the period the company received research grants totalling £100,000 ( 2024 - £150,000 ) from the ABPI.

During the period, the group and company incurred support costs totalling £395,592 and £115,456 respectively ( 2024 - £443,280 and £208,350 ), which were recharged by the ABPI (refer to Note 19 below).

During the current and comparative period, the company received a transfer of profits from OHE Consulting Limited, which were transferred as a qualifying charitable donation via Gift Aid (refer to Note 20 below).

Page 31

Docusign Envelope ID: C8A6B2A9-F279-8CA8-81E2-613F55D85C5F

THE OFFICE OF HEALTH ECONOMICS (A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

19. Ultimate parent undertaking and controlling party

The ultimate parent undertaking and controlling party is considered to be the Association of the British Pharmaceutical Industry Limited ("the ABPI"), registered in England and Wales, 09826787, by virtue of it being the sole member of the company. The Association represents innovative research based biopharmaceutical companies, large, medium and small, leading an exciting era of bioscience in the UK. This company prepares consolidated financial statements. These are available to the public and may be obtained from 2nd Floor Goldings House, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB.

20. Principal subsidiaries

The following was a subsidiary undertaking of the company:

Name Country of Incorporation Principal activity Holding
OHE Consulting Limited United Kingdom Provision of policy and 100%
strategic expertise on
healthcare and related
matters.

During the period, OHE Consulting Limited, registered company number 09853113, generated income totalling £4,414,549 ( 2024 - £4,204,016 ), and incurred expenditure totalling £3,312,806 ( 2024 - £2,602,333 ), plus interest received of £17,729 (2024 - £13,255 ), generating profits for the period of £1,119,472 ( 2024 - £1,614,938 ). OHE Consulting Limited elected to transfer its profits to the company by way of a qualifying charitable donation via Gift Aid, leaving aggregated assets in OHE Consulting Limited of £1 at the period end.

21. Post balance sheet events

There have been no significant events affecting the group since the year-end.

Page 32